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1 Introduction and Objectives 
1.1 Introduction 
Diseases of the human respiratory tract such as asthma bronchiale, chronic obstruc-
tive pulmonary disease (COPD) or local infections are preferentially treated with med-
icines administered via the pulmonary route. By doing so, the application of compara-
tively low doses is possible and an adequate drug distribution to its site of action is 
reached [1,2]. At the same time, a reduced potential for adverse effects is observed 
compared to an oral or intravenous administration due to minimised systemic expo-
sure of these drugs [3–5]. Besides the treatment of diseases which are locally limited 
to the airways, pulmonary drug delivery is also explored as an alternative to effective-
ly administer small molecules or peptides to treat systemic diseases such as diabetes 
or osteoporosis [6,7]. This is reasoned by a large surface area of the lungs, compara-
tively low local metabolic activity and the possibility to avoid first-pass metabolism [8]. 
In addition, the drug is rapidly distributed due to an extended blood flow [9]. 
A considerable percentage of asthma bronchiale and COPD medication is formulated 
as dry powders intended for inhalation. In order to reach the lower airways, the drug 
needs to have an aerodynamic particle size between 1 and 5 µm [10,11]. Further-
more, an adequate flowability of the powder is mandatory to ensure processability 
and accurate dose-metering. These two requirements stand in direct contradiction to 
each other. For this particular size range, cohesive forces are predominant in relation 
to gravitational forces due to relatively low weight and large surface area of the parti-
cles [12]. To counteract poor flowability and secure dose uniformity as well as pro-
cessability of the powder, two main formulation strategies have been developed, 
namely carrier-free and carrier-based systems. The latter approach comprises coarse 
and desirably inert particles in the size range of 50 – 200 µm with adequate flowabil-
ity. During a blending step, drug agglomerates are broken up while these particles get 
attached to the carrier surface. As drug particles interact with the carrier via adhesive 
forces, these blends are also referred to as interactive mixtures.  
During inhalation, the drug needs to be detached again from the carrier to allow deliv-
ery to the target site. The detachment is triggered by the patient´s inspiration. But at 
the same time, it is widely governed by interparticle interactions between carrier and 
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active pharmaceutical ingredient (API). The extent to which these forces occur is 
highly dependent on physico-chemical properties of carrier and API [13]. Therefore, 
an in-depth understanding of the impact of material characteristics on the aerodynam-
ic performance is needed to overcome the challenges in the development of dry pow-
der inhaler (DPI) formulations, e.g. insufficient drug detachment from the carrier dur-
ing inhalation. Besides the formulation and patient´s inspiratory flow, the inhalation 
device plays a key role for this process. Its conception and dimensioning of the differ-
ent parts have to be evaluated carefully [14]. These determine the dispersion mecha-
nism and trigger the occurrence of turbulences, centrifugal forces and thus, particle-
particle and particle-wall collisions which are key to induce drug detachment. 
1.2 Objectives 
This thesis aims at the investigation of aspects concerning the formulation and the 
device in dry powder inhalation. Although much research has been performed on the 
factors influencing drug delivery, the complex mechanisms that govern drug detach-
ment and deagglomeration of carrier-based formulations still remain unclear. To get a 
more comprehensive understanding of these processes, interparticle interactions be-
tween carrier and API are systemically examined using glass beads (GBs) as a model 
carrier platform. In addition, a detailed investigation on the importance of the inhala-
tion device is conducted with a modular inhaler system. The project has been part of 
the priority program SPP 1486: particles in contact (PiKo) and was funded by the 
German Research Foundation (DFG).  
To examine a broad range of chemical properties, APIs with largely differing hydro-
philicity/hydrophobicity are chosen. Spray drying is used to manufacture API particles 
with uniform characteristics in terms of particle size (< 5 µm), size distribution (nar-
row) and overall shape (spherical). A uniform spherical shape is mandatory since it 
secures the independence of contact area between carrier and API from particle ori-
entation.  
The main part of this thesis focuses on interparticle interactions between carrier and 
API and how they are influenced. This shall also elucidate their impact on the behav-
iour of the formulation. To do so, glass beads were utilised as a model carrier system 
for carrier-based formulations. These present the advantage to achieve a modification 
of one specific material property such as surface chemistry or topography without 
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hardly any change of another. This allows a systematic approach to identify relevant 
parameters and examine their impact on aerodynamic performance. Initially, suitable 
techniques to modify the carrier surface in terms of chemistry and topography and 
consequently interparticle interactions are explored and presented. Resulting material 
and bulk properties are characterised using various methods. Suitable blending pro-
tocols are applied to manufacture blends consisting of GBs and drug with sufficient 
content uniformity and also to ensure integrity of the drug. 
It is further investigated how material properties and thus, API-carrier interactions af-
fect drug load and aerodynamic performance. These findings shall contribute to a 
successful design of new and the optimisation of current DPI formulations.  
In addition, the influence of the inhalation device, or more precisely its dimensioning, 
for an optimal drug delivery is examined. The comparison of the results to a previous 
study which utilised lactose as carrier shall emphasise practical differences and simi-
larities when using a conventional carrier or the model carrier system. In addition, im-
pact of API properties on its deposition is examined. These include size, shape, crys-
tallinity and chemical structure and expand the factors under investigation from device 
and carrier to the API. 
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2 Theoretical Background 
2.1 The Human Respiratory Tract  
The human body relies on a continuous supply of oxygen to maintain physiological 
functions. This is ensured by the respiratory system which facilitates the uptake of 
oxygen and the release of waste carbon dioxide.  
It consists of two major parts. The first one (upper part) comprises airways from 
mouth and nose to the pharynx and larynx. These are followed by the lower respirato-
ry tract consisting of trachea, bronchi, bronchioles and the alveolar ducts (Figure 2-1). 
These are lined with around 300 million blood vessel-covered alveoli where gas ex-
change actually takes place. By that, a 23-fold branching with a steady increase in 
total cross section is reached [15]. This leads to a very high surface area of 80 – 
90  m² [16]. Alveolar cells form a very thin epithelium (~ 0.1 µm) which ensures, in 
combination with a lung perfusion, the fast uptake of oxygen. This leads to a rapid 
distribution of drugs. 
 
Figure 2-1 Schematic structure of the lower respiratory system (left) with the resulting 
total cross sectional area (right); adapted from Thews et al. [17] 
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2.2 Pulmonary Drug Delivery 
Inhalation therapy is the most common approach to treat respiratory diseases such as 
asthma bronchiale or COPD. This allows a lower dose and a better side-effect profile 
compared to systemic administration of these drugs. In addition a rapid onset of ac-
tion is maintained. This is especially important in case of an acute asthma attack. 
Medication to locally treat asthma comprises substance classes with extensively dif-
fering mechanisms of action including long- and short-acting ß2-agonists, inhaled cor-
ticosteroids and muscarinic antagonists [18].  
In recent years, the pulmonary route has been explored to deliver systemically active 
drugs currently only available to a parenteral administration. These include peptides 
and proteins such as insulin or growth hormones which are unstable upon oral admin-
istration. Moreover, the lungs provide a large number of immunocompetent cells pre-
sent on the mucosa. This opens up the opportunity for a vaccination against many 
diseases, e.g. pneumonia through pulmonary administration [19]. 
The importance and the recognised potential of pulmonary drug delivery demand a 
deep understanding of parameters which govern the aerodynamic performance of 
these formulations. This knowledge will contribute to an optimisation of currently mar-
keted medicines and also provides the basis for the development of new products. 
2.2.1 General Considerations for Inhalation Products 
The aerodynamic diameter (𝑑𝑎𝑒) is the most suitable parameter to characterise parti-
cles intended for inhalation. It is defined as the diameter of a sphere of unit densi-
ty (1000 kg/m³) which would have the same terminal velocity as the particle under 
investigation [20]. It is calculated according to equation 1. 𝑑𝑔𝑒𝑜 is the geometric di-
ameter of the sphere, 𝜌𝑝 and 𝜌0 are the particle and unit density, respectively. χ is 
defined as the so-called shape factor. It is defined as the ratio of the drag force expe-
rienced by the respective particle to that of a perfect sphere with the same vol-
ume [21].  
𝒅𝒂𝒆 =  √
𝝆𝒑
𝝆𝒐∗𝟀
∗ 𝒅𝒈𝒆𝒐  equation 1 
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Relating this to an example of practical relevance it means: the size of a large porous 
particle with a density of 100 kg/m³ [20] can be increased up to 25 µm and would still 
present the same 𝑑𝑎𝑒 as a drug particle of 2.5 µm with a density of 1000 kg/m³. By 
that, premature impaction in the upper airways can be avoided.  
Drug depositing during inhalation is governed by three mechanisms, namely inertial 
impaction, sedimentation and diffusion (Figure 2-2).  
 
Figure 2-2 Deposition mechanisms of inhaled particles: a) impaction, b) sedimentation 
and c) diffusion 
Airborne particles with a diameter > 6 µm impact on the upper airways. This is due to 
an inertial separation at bifurcations of the airways since these particles are unable to 
follow the directional changes of the airstream [22]. The probability of particle impac-
tion can be described by the dimensionless Stokes number (𝑆𝑡𝑘). As seen in equa-
tion 2, it is influenced by 𝜌𝑝, particle diameter (𝑑), air velocity (𝑉), viscosity of air (ƞ) 
and airway radius (𝑟). Extended depositon triggered by inertial impaction is a major 
challenge which needs to be overcome. This could be the result of an insufficiently 
optimised formulation inducing agglomeration or a persisting attachment of drug to 
the carrier. 
𝑺𝒕𝒌 =
𝝆𝒑∗𝒅
𝟐∗𝑽
𝟏𝟖∗ƞ∗𝒓
  equation 2 
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Secondly, sedimentation occurs for particles with 2 – 6 µm in diameter that enter the 
lower airways, where a low airflow velocity prevails. This is a time-dependent process 
and particles are deposited according to gravitational forces [23]. For particles in the 
respective size range, it can be described by the Stokes-Cunningham equation to cal-
culate the terminal settling velocity 𝑉𝑡𝑠 (equation 3). Here, 𝛥𝜌 is the density difference 
of disperse and dispersed phase, 𝑟 is the particle radius and 𝑔 is the acceleration of 
gravity. In addition, A is a dimensionless factor and 𝜆 is defined as median free path 
length of gas molecules. 
𝑽𝒕𝒔 =
𝟐∗𝜟𝝆∗𝒓𝟐∗𝒈
𝟗∗ƞ
∗ (𝟏 + 𝑨 ∗
𝝀
𝒓
)  equation 3 
The third mechanism applies to small particles (≤ 2 µm) which have not impacted due 
to the two prior processes. Diffusion is observed for small particles reaching the ter-
minal bronchioles and the alveolar region, where airflow is negligible [24]. Here, 
Brownian motion is the dominant force for these particles and can be described by 
equation 4. 𝐷 is defined as the diffusion coefficient, 𝑘 and 𝑇 are the Boltzmann con-
stant and temperature, respectively.  
𝑫 =
𝒌∗𝑻
𝟑∗𝞹∗ƞ∗𝒅
   equation 4 
2.2.2 Drug Application Devices 
Four main groups of inhalation devices are used in inhalation therapy. These include 
nebulisers, pressurised metered-dose inhalers (pMDIs) as well as soft mist inhalers. 
These three are presented briefly, while focus is put on dry DPIs in the following sec-
tion. 
2.2.2.1 Nebulisers 
Nebulisers convert a solution or nano-suspension into an aerosol. This is done by 
different mechanisms such as vibration, ultrasound and pressurised air. They are of-
tentimes prescribed to children and the elderly, as they are easy to use and minimal 
patient training is needed [25]. In addition, dose modification and the application of 
more than one drug are possible [26]. One main reported disadvantage is a varying 
droplet size and consequently a reduced aerosolisation which is triggered by different 
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temperatures [27]. Moreover, most nebulisers are not portable and they are only in-
tended for a stationary use. 
2.2.2.2 Pressurised Metered-Dose Inhalers 
Since the launch of the Medihaler® in 1956, pMDIs have been widely used to deliver 
drugs to the lungs [28]. For these inhalers, the API is either dissolved or suspended 
with an additive propellant, nowadays a hydrofluoroalkane. Portability and the high 
chemical stability of suspension-based pMDIs are two main advantages [29]. But the 
occurrence of physical instabilities, e.g. flocculation or sedimentation oftentimes 
makes the use of further additives such as surfactants and cosolvents necessary. 
But the mandatory precise coordination between inspiration and actuation of the de-
vice has proven to be difficult [30]. In addition, a generally low respirable fraction is 
reached if used incorrectly due to an extensive acceleration of the aerosol. This leads 
to an impaction in the upper part of the airways. These issues can be overcome by 
the use of spacers [31].  
2.2.2.3 Soft Mist Inhalers 
The only soft mist inhaler is the Respimat® introduced by Boehringer-Ingelheim. It 
produces a long lasting aerosol cloud with an overall decelerated velocity compared 
to pMDIs [32]. This triggers a more efficient drug delivery [33]. The independence of 
the emitted dose from the inspiratory flow and simple handling can also be considered 
beneficial. However, production of the device is quite cost-intensive and application is 
limited to an aqueous solution of drugs to this date. 
2.2.2.4 Dry Powder Inhalers 
After the launch of the first DPI in 1971 (Spinhaler®), this device class became in-
creasingly important 17 years later upon the entry into force of the Montreal protocol 
limiting the use of substances harming the ozone layer. This made the exploration of 
alternatives to chlorofluorocarbon-containing pMDI formulations necessary. Due to 
the lack of any liquid components, the physical stability of the API is generally se-
cured. Nevertheless a certain sensitivity to environmental conditions inducing mois-
ture uptake or tribo-charging has been reported [34,35]. 
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DPIs are available as single-dose, multiple unit-dose or multi-dose (reservoir) devic-
es [36]. In general, a single-dose device delivers the medication from a blister (Elpen-
haler®) or a capsule (e.g. Handihaler® and Cyclohaler®) which are placed inside the 
inhaler. Multiple unit-dose devices contain a certain amount of capsules or blisters 
such as FlowCaps® and Diskhaler®. In Multi-dose inhalers, the API is dispensed from 
a reservoir, for example Turbuhaler® and Novolizer®. Dispersion of the formulation is 
triggered by the patient´s inhalation which precludes the need to coordinate device 
actuation with inspiration. By that, handling is facilitated.  
DPIs were used throughout the present work including the Cyclohaler and a Modular 
Inhaler system which is presented in section 3.1.6.2. 
2.3 Formulation Strategies for Dry Powder Inhalation 
The effectiveness of drug delivery to the lungs is highly dependent on correct inspira-
tion by the patient and the used inhalation device. Furthermore, the DPI formulation 
plays a key role in this process. Over the years two main strategies have been pre-
sented for a successful formulation design: carrier-free and carrier-based. The former, 
more recent approach firstly focuses on targeted particle engineering to meet the re-
quirements for successful drug delivery, e.g. by employing large porous parti-
cles [37,38]. Secondly, a controlled agglomeration of spheronised drug parti-
cles (softpellets) can be utilised to improve flowability [39]. This also secures a suffi-
cient aerosolisation upon inhalation if the suitable inhalation device is used. The latter 
approach uses an inert coarse carrier with sufficient flowability to form a so-called in-
teractive mixture with the API.  
Formulation design is critical, as many factors concerning its components have to be 
taken into account which will be discussed in this chapter. Ambient conditions poten-
tially influence forces prevailing within the formulation as well.  
2.3.1 Manufacturing of Drug Particles for Inhalation 
In order to obtain API particles in the suitable size range, different techniques have 
been introduced over the years. These can mainly be classified into two categories, 
namely top-down and bottom-up processes [40]. Micronisation via milling is a typical 
example for a top-down process where a high energy input is needed to reduce the 
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size of larger crystals [41]. One main disadvantage is a possible post-micronisation 
relaxation which causes a change in size and surface area over time [42]. Bottom-up 
processing includes the formation of particles from, for example, a solution. Here, 
precipitation has been used with a major advantage to manufacture particles consist-
ing of more than one drug [43]. This method can also be applied to poorly (water-) 
soluble drugs using an aerosol solvent extraction system and supercritical carbon di-
oxide [44].  
Another example for a bottom-up process to manufacture micron-sized particles is 
spray drying (SD). Properties of the product are highly dependent on solubility, diffu-
sion rate and surface activity of the drug molecules in the atomised droplets [45]. This 
process oftentimes results in amorphous pharmaceuticals with a spherical shape 
which are characterised by a narrow size distribution compared to micronisation by 
milling [46,47]. Particle properties can be tailored to meet requirements for pulmonary 
drug delivery by the control of respective process parameters [48]. In addition, the 
product is characterised by a uniform composition. For these reasons, spray-drying is 
employed for the manufacturing of API particles in the present work.  
Another approach is spray-freeze drying which typically involves a solution that is at-
omised into a chamber filled with a cryogenic liquid (liquid nitrogen) and is subse-
quently freeze-dried. By doing so, amorphous low density particles with a high specif-
ic surface area are obtained [49]. Although an overall higher yield can be reached 
compared to conventional spray drying, it is a cost-intensive and rather time-
consuming procedure [50]. 
2.3.2 Carriers in Pulmonary Drug Delivery 
In order to increase flowability and processability of an inhalation powder, a coarse 
carrier is oftentimes added to the drug. A suitable carrier should meet several criteria 
such as physico-chemical stability, biocompatibility, easy accessibility and production 
at low costs. Moreover, it must be inert to prevent chemical reaction with the API and 
should show good flowability. However, the introduction of a carrier causes a signifi-
cant dependency of the aerodynamic performance on interparticle-interactions be-
tween drug and the carrier. Current DPI products are mainly utilising α-lactose mono-
hydrate, while mannitol is continuously gaining interest as alternative excipient.  
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2.3.2.1 α-Lactose Monohydrate 
Despite recent advances in particle engineering, carrier-based formulations are still 
the most commonly used approach for a targeted drug delivery to the lungs. The car-
rier of choice is α-lactose monohydrate with a wide range of pharmaceutical grades 
for inhalation with different physico-chemical properties available [51]. Lactose has 
been extensively examined as carrier and its beneficial toxicity profile is well-
documented [52]. However, it belongs to the class of reducing sugars which are ca-
pable of reacting with amine groups of other molecules, e.g. amino acids. As a con-
sequence, an API molecule could undergo a chemical reaction which oftentimes 
causes a loss of activity [53]. This disqualifies lactose for formulations with peptides or 
proteins. This drawback, inter alia, has put focus on the exploration of further potential 
carriers. 
2.3.2.2 Other Organic Carriers   
Mannitol is a non-reducing sugar alcohol described as being less hygroscopic than 
lactose [54]. It has been introduced as the most promising candidate as alternative 
carrier for DPI formulations [55]. Mannitol has an extended osmotic effect, which is 
why it is employed as active in Bronchitol®, a currently marketed medicine against 
cystic fibrosis [56]. Recently, spray drying was presented as a suitable technique to 
manufacture spherical mannitol carrier particles with good flowability. By that, physi-
co-chemical properties of the product could be modified as well [57]. 
Further sugars and sugar alcohols such as glucose, sorbitol, maltitol and xylitol have 
been examined but exhibited only minor respirable fractions, mainly due to their in-
creased hygroscopicity [52,58]. 
2.3.2.3 Model Carrier System: Glass Beads 
Many studies have been presented in which a specific property of lactose was modi-
fied to subsequently investigate its impact. However, other material characteristics 
have been also altered unintentionally during the respective processes. For example, 
the change of carrier size generally alters surface roughness or varying the polymor-
phic form can result in a change in both crystal lattice and shape [59]. This essentially 
complicates interpretation of gained results since potential changes in respirable frac-
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tion cannot be explicitly attributed to that respective modification. To overcome this 
issue associated with the use of conventional carriers, the present work employed 
glass beads as model carrier system for studies shown in this thesis. These are avail-
able in a wide range of size. Moreover, the manufacturing process ensures a uniform 
spherical shape and a reproducible state of the surface. This qualifies GBs for an ide-
al system to selectively investigate the impact of carrier modification on interparticle 
interactions. GBs in the size range of 400 – 600 µm were employed, while the chosen 
size presents a compromise between the normal diameter of a carrier (50 – 200 µm) 
and the suitability to conventional inhalation characterisation techniques described in 
section 3.4. To the authors´ knowledge, no studies apart from those within the DFG 
priority program have been conducted to examine interactions between carrier and 
API by such a systematic approach. Although GBs are basically only applicable to in 
vitro experiments due to safety concerns, gained results will help to further elucidate 
explain interparticle interactions in DPI formulation. Consequently, present findings 
will contribute to further optimise the currently marketed as well as newly developed 
formulations. 
2.3.3 Interparticle Interactions 
2.3.3.1 General Considerations for DPI Formulations 
The formation of interactive mixtures for dry powder inhalation is generally considered 
a two-step process of drug deagglomeration and drug adhesion onto the carrier sur-
face [60]. Fracture of larger drug agglomerates is initially obtained by impact of parti-
cles with the coarse carrier and the walls of the mixing vessel. After this, drug parti-
cles are completely deagglomerated and deposited onto the carrier surface due to 
forces arising from friction between drug and carrier and/or the mixing vessel [61]. 
It can be concluded that the blending process depends on the magnitude of cohesive 
and adhesive forces of the particles. The former refer to interaction between particles 
of the same kind while the latter describe the interaction between different materials. 
Cohesive forces of drug particles need to be low enough to be overcome by shear 
forces created during blending and to prevent reagglomeration [62]. The formation of 
interactive mixtures is energetically favoured if the adhesive forces are stronger than 
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cohesive forces of the drug [63]. But as far as adhesion is concerned, excessive forc-
es between carrier and API potentially prevent the latter from being readily detached 
during inhalation. This would lead to a deposition in the upper airways [64] (Figure 
2-3). Nevertheless, a sufficient attraction to the carrier is mandatory to ensure blend 
homogeneity and impede segregation during handling. In this context, the importance 
of the cohesive-adhesive balance (CAB) has been acknowledged which is essential 
to meet the requirements for a DPI formulation [65]. Moreover, the CAB ratio between 
cohesion of the drug and its adhesion to the carrier has already been used to explain 
and predict the aerodynamic performance of different interactive mixtures [66,67].  
Adhesion and cohesion are dependent on three different kinds of forces: van-der-
Waals, capillary and electrostatic forces [68]. The extent to which these occur in the 
interactive mixture is determined by material characteristics of the components as 
well as environmental conditions, i.e. temperature and relative humidity (rH) [69]. Ad-
hesive forces are particularly important for DPI formulations. The API exhibits high 
surface area/mass ratio due to its small size. Therefore, attractive forces are signifi-
cantly higher than the gravitational separation forces [60]. For a powder blend con-
taining a carrier of 200 µm and an API of 5 µm, for example, the adhesion exceeds 
the respective separation force by a factor of 3x105. 
 
Figure 2-3 Formation and disintegration of an interactive mixture 
Van-der-Waals forces are non-covalent interactions consisting of three main compo-
nents. Firstly, Keesom forces describe interactions between two permanent dipole 
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molecules. Secondly, Debye interactions between a permanent dipole and a molecule 
with an induced dipole and thirdly London dispersive forces that arise from molecules 
with induced dipole moments. Due to mobility of electrons within a certain area (elec-
tron cloud), temporary dipoles can be induced within a molecule. Hereafter, this mole-
cule is capable of triggering dipole moments within other molecules. The extent of 
van-der-Waals forces can be manipulated by limiting contact area which is subject of 
the present work and/or increasing distance between carrier and API. 
At elevated rH, capillary forces arise from the presence of adsorbed water on the par-
ticle surface. This is caused by the condensation of water vapour. If such particles 
come into intimate contact, a concave-shaped liquid meniscus is formed inducing a 
comparatively strong cohesion/adhesion [70]. Consequently, drug detachment and 
deagglomeration is impeded. The formation and the extent of these liquid bridges are 
mainly dependent on ambient conditions and hygroscopic behaviour of the particles. 
While the development of liquid bridges is generally a matter of minutes to hours, the 
formation of solid bridges can occur during long term storage at increased rH [71]. 
This can be the case for materials with enhanced water solubility, where a dissolution 
and subsequent solidification of molecules on the surface potentially takes place. This 
leads to either an increase in drug particle size and/or a persisting attachment to the 
carrier surface, which ultimately impedes the aerodynamic performance. 
In contrast, electrostatic forces may prevail at lower rH. These generally occur when 
two different materials come into contact and separate afterwards [72]. In DPI formu-
lations, carrier and API are generally organic and insulating materials, which is why a 
net charge of both materials during this process due to electron transfer can be ex-
pected. These interfacial charges can increase adhesion between carrier and API. 
This is especially important for DPI formulations as electrostatic forces were found to 
be primarily induced by particle-particle and particle-wall friction. This occurs within 
the device during inhalation manoeuvre and in the mixing container during blending. 
However, electrostatic charge can be reduced by increasing rH. The resulting absorp-
tion of water enhances surface conductivity and triggers electron exchange between 
particles with an opposite net charge [69]. 
Both capillary and electrostatic forces are highly dependent on material characteris-
tics. In addition, while certain ambient conditions give rise to one of them, the other 
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one is reduced. This highlights the importance of a balance of ambient conditions. For 
this, ideal temperature and rH for processing and storage have to be determined 
for the formulation components to keep both forces as low as possible. 
Forces described above are triggered by a variety of different factors. The most im-
portant ones are displayed in Figure 2-4. In the present work, focus was put on carrier 
surface topography and chemistry, while the impact of API to carrier ratio was investi-
gated as well. 
 
Figure 2-4 Overview of parameters influencing interactions between carrier and API in 
a DPI formulation: particle characteristics (purple), formulation properties (blue) and 
further intrinsic properties (light blue) adapted from [73] 
2.3.3.2 Impact of Particle Properties on Interparticle Interactions 
Material characteristics of carrier and API play an important role in the process of 
drug deagglomeration and detachment. Here, the control of particle size is crucial. 
The smaller the drug particles, the higher the adhesive forces due to the decreased 
surface area/mass ratio provided that other parameters are kept constant. This would 
actually favour larger particles for an optimal drug detachment. However, these parti-
cles would impact in the upper airways due to inertial impaction. The effect of carrier 
size on aerodynamic performance has been widely investigated with different results. 
Steckel and Müller found a general reduction of the respirable fraction for larger carri-
ers [74]. This might be ascribed to an increased number of particle collisions and a 
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higher overall frictional area provided by the smaller carrier. This was also confirmed 
by another study which noted, however, that a decrease in carrier diameter also forc-
es poor dose uniformity [75]. In contrast, increased aerodynamic performances 
gained from larger carrier size fractions has also been reported [76]. Since larger car-
riers showed improved flowability and minimised dose variability, they exhibited an 
overall enhanced performance. It is assumed that these conflicting results are derived 
from interdependency between physical properties and also relies on the choice of 
device. Increased carrier size, for example, might be more favourable when using an 
inhaler relying on inertial impaction for drug dispersion due to an increased particle 
momentum.  
Carrier morphology can influence the aerodynamic performance as well, since parti-
cles with different shapes are affected differently by drag forces. It was shown that an 
elongated morphology is favourable for an effective drug deposition [77]. This is be-
cause an elongated carrier potentially exhibits a considerably smaller aerodynamic 
diameter compared to a spherical particle with the same volume and mass [78]. 
Therefore, these particles can follow the air stream for a prolonged period of time so 
that API particles on the carrier are longer exposed to the detachment forces. The 
shape of the API might have a substantial influence on adhesion as well, since it de-
termines the contact area with the carrier and therefore interparticle forces. For in-
stance, a perfectly round particle provides fewer contact area compared to elongated 
ones on a smooth surface. But needle-like particles also showed an enhanced lung 
deposition due to a smaller aerodynamic diameter compared to spherical particles 
with similar density [79].  
Even though the impact of carrier topography, or more precisely surface roughness, 
has been investigated, conflicting reports have been published. On the one hand an 
enhanced drug detachment from carriers holding an irregular surface has been pre-
sented [80]. This was confirmed by Zellnitz et al. within the PiKo priority program, 
where the surface roughness of glass beads has been increased through, inter alia, 
plasma etching [81]. This beneficial effect was ascribed to a reduction of contact area 
between carrier and API. On the other hand, a reduced aerodynamic performance of 
blends consisting of carrier particles with a rough surface was demonstrated as well. 
Flament et al. attributed this to an increase in contact points of carrier and drug to en-
hance adhesive forces [82]. These findings were also supported by another 
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study [78]. One reason for the varying results might be an inaccurate definition of 
“rough” and “smooth”. Moreover, the oftentimes missing clarification of the scale of 
roughness might accountable. But even more important seems a concurrent alteration 
of other material properties such as size or overall shape triggered by the respective 
surface modifications. This makes a distinction of the effects resulting from the differ-
ent modifications very difficult.  
In contrast, only little information about the importance of chemical properties for the 
interaction potential of carrier and API is available at the moment. Traini et al. investi-
gated polymorphic forms of lactose in respect to their surface energies [83]. They 
found a negative correlation between surface energy and respirable fraction which 
was attributed to the different extent of adhesion forces (AFs) in the interactive mix-
ture. However, only a narrow range of properties could be examined, since the differ-
ent lactose grades exhibited rather similar energies.  
2.3.4 The Inhalation Device 
A typical dry powder inhaler has three main features such as mouthpiece, powder 
deagglomeration chamber and one or more air inlets. With a few exceptions this ap-
plies to all devices regardless of single- or multi-dose. The conception of these parts 
governs flow properties within the device and determines the prevailing dispersion 
and detachment mechanisms. This is particularly important as certain properties of 
the formulation might be beneficial for the aerodynamic performance using one de-
vice, but may be ineffective or even disadvantageous for another device. 
The Cyclohaler for example is a device with a widely straightforward assembly (sec-
tion 3.1.6.1). Here, a capsule rotates in the chamber triggered by patient´s inspiratory 
air flow. By that, the powder blend gets released from the capsule. Drug redispersion 
is based on drag and lift forces arising from the different velocities of airstream and 
particles [84]. This device was chosen for impaction analysis in the present thesis for 
two main reasons: Firstly, a single-dose device was needed as dose-metering sys-
tems of available inhalers do not function effectively with the large GB carriers. Sec-
ondly, its comparatively simple design enabled numerical simulations within the PiKo 
priority program by the working group of Professor Sommerfeld from the University of 
Halle concerning drug detachment in the device [85]. 
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One commonly-used reservoir device is the Novolizer® which presents a more sophis-
ticated design. A build-in classifier secures a controlled circulation time of the interac-
tive mixture to optimise the use of the available energy provided by the airstream for 
dispersion [86]. Due to its conception, drug detachment and deagglomeration are 
mainly triggered by inertial and frictional forces which are considered as most effec-
tive [84]. This is beneficial for rather large carriers. 
In general, a device should deliver a precisely metered dose to the target site with a 
high efficiency. It should also be easy to use and least susceptible to incorrect han-
dling by the patient. In addition, a high independence from the patient´s inspiration is 
desirable to ensure reproducibility of dose and make it available to all patient groups 
such as children or elderly with limited lung function. In recent years, effort has been 
made to optimise the inhalation device in respect to these requirements. Friebel, for 
example, developed a new DPI named the Unihaler which was optimised by using 
different freely combinable inhaler parts in different dimensions [87]. This so-called 
modular system (section 3.1.6.2) is also employed as a device system in the present 
thesis. 
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3 Materials and Methods 
3.1 Materials 
The APIs utilised in the present work are common medications in the treatment of 
asthma bronchiale or COPD. They were selected based on their physico-chemical 
properties to cover a wide range of hydrophilicity/lipophilicity (Table 3-1). Thus, com-
plexity of interparticle interactions could be elucidated to a further extent.  Moreover, 
the chosen APIs were used in spray dried (sd) and/or micronised (micro) quality de-
pending on the requirements profile of the respective study. 
Table 3-1 Physico-chemical properties of used APIs [88–91] 
API Molecular weight, g/mol Solubility LogP 
Budesonide 
(BUD) 
430.5 Insoluble in H2O 2.7 
  
 Soluble in methylene chloride 
 
    
Formoterol 
fumarate (FF) 
478.5 Poorly soluble in H2O 1.06 
  
Soluble in methanol 
 
    
Ipratropium 
bromide (IB) 
430.4 Soluble in H2O -1.8 
    
Tiotropium 
bromide (TB) 
472.4 Sparingly soluble in H2O -1.7 
3.1.1 Model Drugs  
3.1.1.1 Budesonide 
BUD belongs to the substance class of inhaled corticosteroids (ICSs). Reducing hy-
per-responsiveness of the airways as well as decreasing the production of inflamma-
tory mediators and mucus is the proposed effect mechanism of action [92]. Due to its 
beneficial high ratio of topical anti-inflammatory to systemic activity, it is routinely used 
in the treatment of asthma bronchiale [93]. Furthermore, in vitro tests have shown a 
200-fold higher affinity to the glucocorticoid receptor than cortisol [94]. BUD is part of 
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long-term control medication which patients are supposed to take regularly to keep 
chronic symptoms to an acceptable minimum and also prevent asthma attacks [95]. It 
is marketed as single preparation with a dose of 200 µg (children) – 400 µg (adults) or 
as combination product with formoterol fumarate. The structural formula is illustrated 
in Figure 3-1. 
 
Figure 3-1 Chemical structure of BUD 
3.1.1.2 Formoterol Fumarate 
FF is a fast-acting ß2-agonist which additionally has a prolonged effective period of up 
to 12 hours due to its ability to permeate and be stored in smooth muscle cell mem-
branes. In contrast to other existing ß2-agonists, it has an enhanced intrinsic efficacy 
at its receptor [96]. Binding to the ß2-adrenoceptor leads to bronchial dilatation caus-
ing a persisting expansion of the lower airways. FF has gained approval for the thera-
py of COPD and is also used in the treatment of asthma bronchiale [94]. In case of 
the latter, it is administered as single or combination product with BUD, for exam-
ple [97]. In general, only a very low dose of 9 – 12 µg is needed due to its high poten-
cy. The chemical structure is shown in Figure 3-2. 
 
Figure 3-2 Structural formula of FF dihydrate 
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3.1.1.3 Ipratropium Bromide 
IB serves as a short-acting muscarinic antagonist (SAMA) [98]. Administration of IB 
leads to a dilatation of smooth muscle cells triggered by the antagonism at muscarinic 
receptors. The combination of IB and salbutamol sulphate (SBS) is well established 
as medication on demand in 2nd line therapy of asthma bronchiale. It is also indicated 
in the treatment of COPD [99]. The marketed combination product (Combivent®) de-
livers a dose of 120 µg SBS and 20 µg IB. Its structural formula can be found in Fig-
ure 3-3. 
 
Figure 3-3 Chemical structure of IB 
3.1.1.4 Tiotropium Bromide  
TB belongs to the drug class of long-acting muscarinic antagonists (LAMAs). A decel-
erated dissociation from the muscarinic receptor compared to IB ensures a prolonged 
effective period and allows a once-daily administration. Present guidelines advise the 
application of, inter alia, LAMAs as first-line treatment of COPD to reduce its symp-
toms and exacerbations [100]. Additionally, TB has recently been added to the Global 
Initiative for Asthma Treatment Strategy as an alternative for addition at steps 4 and 5 
in adult patients with asthma bronchiale [101]. TB is currently marketed as an aque-
ous solution for soft mist inhalers and as a DPI formulation with doses of 2.5 µg and 
18 µg, respectively. The chemical structure is illustrated in Figure 3-4. 
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Figure 3-4 Structural formula of TB 
3.1.2 Glass Beads  
In this study, GBs in the size range of 400 – 600 µm (manufacturer specification) 
were used as a model carrier system. They are made of soda-lime glass with its main 
component being silicon dioxide, further consisting of sodium oxide, calcium oxide, 
magnesium oxide and aluminium oxide [102]. Soda-lime glass accounts for the larg-
est proportion of industrially manufactured glass and is widely used, for example in 
building or food industry.  
 
Figure 3-5 Schematic drawing of the structure of soda-lime glass used for GB manu-
facturing 
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The GBs (SiLibeads Type S®, Sigmund Lindner GmbH, Warmensteinbach, Germany) 
are characterised by a high hydrolytic (class HGB2, based on DIN ISO 720) and acid-
ic (class S2, according to DIN 12116) resistance and additionally show maximum re-
sistance to alkalines (class A1, according to DIN ISO 695) [102]. The glass structure 
can be taken from Figure 3-5. 
3.1.3 Tungsten Carbide 
Tungsten carbide (TC) is amongst nature´s hardest materials with 9.5 on the Mohs 
scale of hardness (Diamond: 10.0). Due to its robustness, TC is frequently used in the 
industry as raw material for the manufacturing of mechanically highly stressed tools 
like drills or milling machines. These characteristics qualify TC for grinding of the GB 
carrier surface. 
TC powder HTWC 250 (Wolfram Bergbau und Huetten AG, St. Martin i.S., Austria) 
with a nominal grain size of 25 µm was employed as grinding material for physical 
surface alteration of GBs.  
3.1.4 Hydrofluoric Acid 
Hydrofluoric acid (HF) is a common industrial agent for wet chemical etching of metal 
or glass surfaces. For instance, HF is used in the manufacturing of wafers to control 
the thickness of the respective silicon layer [103]. Furthermore, it has been presented 
as a suitable agent to adjust the diameter of optical fibres [104]. This is due to its ca-
pability to readily dissolve silicate glass even at room temperature which makes HF a 
suitable chemical product for the alteration of GB surfaces.  
Concentrated HF (40 %) was purchased from Merck Millipore (Darmstadt, Germany). 
3.1.5 Capsules 
Prior to filling, capsules were stored in a desiccator for 24 hours to maintain a brittle 
state of the material. Due to the large carrier size, this conditioning step was needed 
to ensure the release of the interactive mixture during inhalation manoeuvre.  
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Hard gelatin capsules of size 3 (CAPSUGEL, Morristown, USA) were utilised in the 
present study. 
3.1.6 Inhalation Devices 
3.1.6.1 Cyclohaler 
The Cyclohaler (Figure 3-6) is a passive inhalation device and is therefore fully relying 
on the patient´s inspiration capacity. It delivers a single dose of powder blend from a 
hard gelatin capsule [105]. The Cyclohaler belongs to the group of low resistance in-
halers, since a very high flow rate has to be applied to reach the mandatory pressure 
drop of 4 kPa defined by the Ph. Eur. [106]. 
 
Figure 3-6 Commercially available Cyclohaler 
3.1.6.2 Unihaler/Modular Inhaler 
The Unihaler was developed by Christian Friebel at Kiel University in the course of his 
doctoral thesis where several parts of the inhaler including the opening mechanism 
for the capsule, air-conducting parts, deagglomeration chamber and mouthpiece have 
been designed and optimised [87]. This ultimately led to the final concept. The optimi-
sation was realised using a so-called modular inhaler system, whereby the differently 
dimensioned parts could be freely combined (Figure 3-7). 
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Figure 3-7 Design of the Modular Inhaler with upper part, grid and bottom part 
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3.2 Statistical Methods 
3.2.1 Design of Experiments 
Conventional approaches used for the finding of optimal experimental conditions are 
“trial and error” or changing of just one factor at a time. These methods are usually 
very time- and resource-consuming and do not lead to the desired outcome at all 
times. DoEs however, provide the possibility to efficiently evaluate processes which 
are characterised by a high degree of complexity. For this purpose, various factors 
and their levels are selectively combined leading to an empirical model. This reflects 
the influence of the included factors on the defined responses as well as the relation 
of different factors [107]. Table 3-2 provides an overview of common terms in experi-
mental design. 
Table 3-2 Common terms in experimental design 
Term Definition 
Factor Influence quantity selected for the respective trial 
       Quantitative Can accept arbitrary values within a certain range, 
 
e.g. temperature or concentration 
       Qualitative Can solely accept certain values, e.g. "on" and "off" 
  
Factor levels Values of respective factor used in the study 
  
Response Objective criterion, e.g. particle size or yield 
  
Effect Impact of factor on response 
 
In general, a variety of different designs is available whereby the choice of the appro-
priate one is dependent on the scientific question. For this thesis, a central composite 
face design (CCF) with three factors varied on three different levels was used. The 
resulting setup is illustrated in Figure 3-8. Each point represents a single experimental 
setup. The centre point (CP) was repeated five times to investigate reproducibility and 
validity of the model resulting in a total of 19 runs. This applies to all DoEs presented 
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in this work. Initially, every term under investigation was considered. For the present 
setup with three factors, the respective responses (𝑅) were evaluated based on equa-
tion 5:  
𝑹 = 𝒄𝟎 + 𝒄𝟏𝒇𝟏 + 𝒄𝟐𝒇𝟐 + 𝒄𝟑𝒇𝟑 + 𝒄𝟒𝒇𝟏
𝟐 + 𝒄𝟓𝒇𝟐
𝟐 + 𝒄𝟔𝒇𝟑
𝟐 + 𝒄𝟕𝒇𝟏𝒇𝟐 + 𝒄𝟖𝒇𝟏𝒇𝟑 + 𝒄𝟗𝒇𝟐𝒇𝟑 
This equation also takes possible quadratic relations and interactions between factors 
into account. Here, 𝑐𝑥 and 𝑓𝑛 are defined as coefficients and factor levels. To ensure 
an adequate model fit for the DoE, insignificant terms were disregarded from the re-
spective equation for each response. The quality of the models was evaluated based 
on criteria listed in Table 3-3. 
 
Figure 3-8 Illustration of the CCF design applied for respective DoE approaches in this 
study 
Generation as well as evaluation of DoEs was carried out using the MODDE 10.1.1 
software (Umetrics AB, Umeå, Sweden). 
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Table 3-3 Parameters for the evaluation of design quality 
Parameter Definition Target value 
R2 
Shows the model fit and is an indicator 
for model significance 
> 0.5 indicate significant   
model 
   
Q2 Indicates future prediction precision > 0.5 is desirable 
   
Model validity 
Indicates presence/absence of diverse 
model problems 
>  0.25 is mandatory* 
   
Reproducibility 
Variation of replicated centre points 
compared to overall variability 
> 0.5 is desirable 
* might be very low due to an artificial lack of fit if reproducibility is > 0.9 
3.2.2 General Statistical Considerations 
Unless otherwise stated, measurements were performed in triplicate in the present 
study to determine the mean value and standard deviation (StD), which is represent-
ed by error bars in the respective graphs. If necessary, data was subjected to analysis 
of variance (ANOVA) and Student´s t-test (Microsoft Excel 2010 (Microsoft Corpora-
tion, Redmond, USA)) with a probability value (p-value) of < 0.05 considered being 
statistically significant.   
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3.3 Preparative Methods 
3.3.1 Spray Drying of Model Drugs 
SD, being a one-step process, is a useful technique to create particles in the size 
range desirable for inhalation [108,109]. It also allows a selective alteration of not only 
particle size, but also shape and morphology by modifying process conditions [110]. 
The final product is typically characterised by a narrow particle size distribution (PSD) 
which is also considered as beneficial for pulmonary application [111]. Due to a com-
paratively low heat stress applied, this technique can even be used for thermosensi-
tive biomolecules like peptides [112,113]. Nevertheless, one potential disadvantage of 
this process is that it often leads to a phase change of crystalline raw material result-
ing in particles in the amorphous state. This may essentially complicate powder han-
dling [114]. Strategies to cope with this issue are explained in detail in Section 3.3.3. 
In the course of SD, an API solution, a suspension or a colloidal dispersion is atom-
ized by a nozzle creating a large number of droplets, while the solvent is quickly 
evaporated by the co- or anti-current drying gas stream. Solidified API particles are 
separated in a cyclone based on centrifugal forces and are collected afterwards in a 
bottom collecting vessel (Figure 3-9 (left)). As the desired particle diameter is 
1 to 5 µm, the spray drying parameters inlet temperature (Tinlet), feed rate (FR), feed 
concentration (FC), spray gas flow (SGF) and drying gas flow (DGF) have to be cho-
sen thoughtfully. Based on preliminary tests, fixed and varying parameters as well as 
their ranges were specified and provided the basis for the DoEs described in the fol-
lowing sections. 
All trials were carried out with a B290 Mini Spray Dryer (Büchi Labortechnik AG, Swit-
zerland) equipped with a high performance cyclone (Figure 3-9 A). Aqueous solutions 
were processed in open cycle mode, where heated air led to solvent evaporation. Due 
to safety reasons, the B290 was connected to a B295 Inert Loop (Büchi Labortech-
nik AG) and was operated in closed cycle mode when working with organic sol-
vents (Figure 3-9 (right)). Here, nitrogen was used as drying gas to create inert condi-
tions and prevent the danger of potential explosion. After passing the spray dryer, 
nitrogen is led into the inert loop, where separation of the organic solvent is taking 
place at a refrigerator unit while the nitrogen is brought back into the system. The final 
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products were stored in a desiccator over silica gel (Sigma Aldrich Chemie GmbH, 
Munich, Germany) immediately until further use. 
 
Figure 3-9 Setup of the Büchi B290 Mini Spray Dryer (left) equipped with a B295 Inert 
Loop (right) 
3.3.1.1 Budesonide 
In the present study, BUD was used as a hydrophobic model drug in micronised quali-
ty (Minakem SAS, Dunkerque, France) and additionally as spray-dried material for 
research purposes. For the latter, an appropriate amount of drug was dissolved in 
methylene chloride. In order to obtain particles in the suitable size range, Tinlet, FR 
and FC were varied on three different levels, while SGF and DGF were kept constant. 
Detailed information about SD conditions for the APIs can be taken from Table 3-4. 
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Table 3-4 SD conditions for different APIs 
API Tinlet, °C FR, mL/min FC, %(w/w) SGF, L/h DGF, m³/h 
BUD 80, 100, 120 3.2, 4.3, 5.4 2.5, 5.0, 7.5 414 40 
      
FF 100 2.1, 3.2, 4.3 2.5, 5.0, 7.5 334, 380, 426 40 
      
TB 120, 135, 150 3.7 2, 3, 4 380, 438, 496 40 
 
3.3.1.2 Formoterol Fumarate 
FF was engaged as a model drug with intermediate hydrophilicity forming a link be-
tween hydrophobic BUD and hydrophilic IB/TB. It was used as micronised (Vamsi 
Labs Ltd., Maharashtra, India) and spray-dried material. For the latter FR, FC and 
SGF were varied to obtain inhalable particles. The SD solution was prepared by dis-
solving the adequate amount of FF in methanol, wherefore the process was per-
formed in closed cycle mode as well. 
3.3.1.3 Tiotropium Bromide 
Furthermore, the present study included TB (Hangzhou Hyper Chemicals Ltd., 
Zhejiang, China) as a hydrophilic model drug. SD of aqueous solutions of the drug 
was performed in open cycle mode aiming at the manufacturing of particles in the size 
range of 1 – 5 µm. Here, Tinlet, FC and SGF were adjusted at constant FR and DGF.  
3.3.1.4 Ipratropium Bromide 
IB served as an additional hydrophilic model drug in the present study. As a conse-
quence of inadequate processability by SD, IB was solely used in micro quality 
(Boehringer Ingelheim Pharma AG & Co. KG, Ingelheim, Germany). 
3.3.2 Modification of Glass Beads 
In order to investigate the effect of carrier surface characteristics on interparticle in-
teractions and consequently on effective drug loading (TSC) and aerodynamic per-
Materials and Methods 
 
32 
 
formance, different methods for selective surface modification have been introduced. 
Before the actual process, GBs were incubated with a standard cleaning solu-
tion (H2O2:NH4OH:H2O 1:1:5) to erase any organic residues and maintain comparable 
surface conditions. This applies to all modification procedures. 
3.3.2.1 Chemical Surface Modification 
For alteration of chemical surface properties, untreated GBs (GB_UT) were incubated 
with ethanolic solutions of various silanes in three different concentrations of 0.005 M, 
0.05 M or 0.5 M for 30 min. Structural formulas of the respective silanes can be taken 
from Figure 3-10. Afterwards, GBs were rinsed several times with double-distilled wa-
ter (ddH2O) and put in a drying chamber at 60 °C to remove residual moisture.  
 
 
Figure 3-10 Silanes used for chemical surface modification: Chlorotiphen-
ylsilane (TPCS), Chloro(methyl)diphenylsilane (CDPMS), Chloro(dimethyl)phenyl-
silane (CDMPS), Chlorotrimethylsilane (CTMS) and Trimethoxy(3,3,3-trifluoro-
propyl)silane (FPTS) 
This work was carried out by cooperation partners of the DFG priority program at the 
Department of Mechanical Process Engineering (Otto von Guericke University, Mag-
deburg).  
3.3.2.2 Alteration of Surface Topography 
HF Treatment 
100 g of GBs were incubated with HF for 10 minutes. After filtration, GBs were rinsed 
several times with ddH2O to wash off acid residues followed by drying and storage in a 
plastic container until further use. 
 
       TPCS                   CDPMS                   CDMPS        CTMS              FPTS 
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Ball Milling 
The second processing method engaged a planetary ball mill where a grinding jar 
rotates in the opposite direction to a counterweight (Figure 3-11). That  induces high 
dynamic energies caused by frictional and impaction forces [115]. 
 
Figure 3-11 Working principle of the ball milling process 
For surface alteration purposes, conventional grinding balls were replaced by TC as 
grinding media (small particles). 100 g of GBs (large spheres) were filled into a zirco-
nium oxide grinding jar with a volume of 500 mL together with the same amount of TC 
and processed with a PM 100 ball mill (Retsch Technology GmbH, Haan, Germany). 
Milling time was set to four or eight hours and rotation speed was adjusted to 
424 rpm. The whole process was conducted in a cold storage room at 1 – 3 °C to 
counteract the heat development created through extensive frictional forces during 
milling. Afterwards, a stainless steel sieve with a mesh size of 355 µm was used to 
separate GBs from the major portion of TC. GBs were then put in a glass vessel filled 
with ddH2O and placed in an SONOREX SUPER RK ultrasonic bath (Bandelin Elec-
tronic GmbH & Co.KG, Berlin, Germany) to detach remaining TC from the glass sur-
face.  
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3.3.3 Working Under Controlled Ambient Conditions 
Preparation (section 3.3.5) and impaction analysis (section 3.4.2.3) of interactive mix-
tures were performed under controlled conditions to maintain stability of the drugs. 
Furthermore, this procedure ensured comparable environmental conditions for all ex-
periments. The parameters temperature und rH were chosen thoughtfully for each 
API based on performed dynamic vapour sorption (DVS) measurements (section 
3.4.1.7). An overview can be taken from Table 3-5. 
Table 3-5 Ambient conditions adjusted for different APIs used in the present study 
API Temperature, °C Relative humidity, % 
BUD sd 21 35 
BUD micro 21 45 
 
  
FF sd 21 30 
FF micro 21 45 
 
  
TB sd 21 20 
 
  
IB micro 21 45 
 
Therefore, blending and impaction analysis were conducted in a climate chamber 
(Imtech GmbH, Hamburg, Germany). 
3.3.4 Calculation of Carrier Surface Coverage-Theoretical Considerations 
As already mentioned, an overarching objective of the present study was to investi-
gate the interparticle interactions between API and carrier. In the course of this, the 
effect of carrier surface modification on drug loading and consequently the influence 
of drug loading on aerodynamic performance should be elucidated. As the use of 
spray-dried, spherical particles provided the opportunity to determine the amount of 
API necessary to cover a certain degree of carrier surface, different so-called theoret-
ical or calculated surface coverages (CSCs) were determined. This was achieved by 
calculating the amount of API needed to be weighed in to cover a defined percentage 
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of the total free carrier surface [81]. Assuming densest sphere packing of API parti-
cles on the GB surface, the projected area of two equilateral triangles, where side 
length is the diameter of a single API particle, equals the space occupied by a single 
drug particle (Figure 3-12). 
 
Figure 3-12 Schematic illustration of CSC determination adapted from [81] 
The surface area (𝑆𝐴𝐺𝐵) of a single GB and the projected area on a GB occupied by a 
single API particle (𝑝𝐴𝐴𝑃𝐼) were calculated based on equation 6 and equation 7. 
Here, 𝑑𝐺𝐵 and 𝑑𝐴𝑃𝐼 represent the diameters of a single GB and an API particle, re-
spectively. In order to determine the total number of API particles needed to cover 
100 % of the surface of one GB, the resulting value from equation 6 was divided by 
the surface area occupied by a single API particle. For other CSCs (50 % and 25 %), 
the resulting value was adjusted accordingly. 
 
𝑺𝑨𝑮𝑩 = (𝒅𝑮𝑩 + 𝒅𝑨𝑷𝑰)
𝟐 ∗ 𝝅  equation 6 
𝒑𝑨𝑨𝑷𝑰 = (
𝒅𝑨𝑷𝑰
𝟐
𝟒
∗ 𝟑𝟎.𝟓) ∗ 𝟐   equation 7 
𝒎𝑮𝑩 = 𝑽𝑮𝑩 ∗ 𝒑𝑮𝑩 = 𝝅 ∗ 𝒅𝑮𝑩
𝟑 ∗
𝒑𝑮𝑩
𝟔
 equation 8 
𝒎𝑨𝑷𝑰
𝑮𝑩
= 𝝅 ∗ 𝒅𝑨𝑷𝑰
𝟑 ∗
𝒑𝑨𝑷𝑰
𝟔
∗ 𝝌  equation 9 
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In a third step, the mass of one single GB particle (𝑚𝐺𝐵) was calculated based on 
equation 8 (𝑉𝐺𝐵: volume of one GB) to determine the number of GBs present 
in 15 g (by dividing 15 g by 𝑚𝐺𝐵). Equation 9 provides the mass of API particles per 
GB, which is multiplied by the calculated number of GBs to display the amount of API 
needed to weigh in for the desired CSC. 𝜒 represents the number of API particles per 
GB for the desired CSC. For illustration purposes, a scheme has been added, where 
calculation steps can be comprehended more easily (Figure 3-13).  
 
Figure 3-13 Illustration of arithmetic steps for determining API net weight for a certain 
CSC 
3.3.5 Preparation of Interactive Mixtures 
Manufacturing of interactive mixtures employed a Turbula blender T2C (Willy 
A. Bachofen AG, Muttenz, Swizerland), where the mixing container is subjected to 
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rotation, translation and inversion to obtain sufficient homogeneity [116]. The basic 
principle is illustrated in Figure 3-14. 
 
Figure 3-14 Rotational movement of the Turbula blender 
For spray dried or micronised API qualities, 15 g or 14.75 g of GBs and the appropri-
ate amount of drug were weighed into a stainless steel mixing vessel using the double 
sandwich method (Carrier/API/Carrier/API/Carrier) resulting in a filling volume of 
around 20 %. For each API, preliminary tests were conducted to determine optimal 
blending parameters, namely time and rotation speed to obtain sufficient blend homo-
geneity (section 3.4.2.2) as well as to ensure integrity of spray-dried and micronised 
API particles. Blending protocols can be taken from Table 3-6 
Table 3-6 Blending parameters for different APIs 
API Blending time, min Rotation speed, rpm 
BUD sd 30 20 
BUD micro 20 30 
   
FF sd 30 20 
FF micro 30 42 
   
TB sd 45 20 
   
IB micro 20 followed by 10 30 followed by 20 
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3.4 Analytical Methods 
3.4.1 API and Carrier Characterisation 
3.4.1.1 Laser Diffraction 
Laser diffraction is a frequently used technique in the pharmaceutical industry and in 
research for investigations concerning particle sizes as it can be applied to solid and 
liquid samples [117,118]. The measuring principle is based on the varying potential of 
particles to diffract laser beams according to their size, whereby larger particles lead 
to higher intensities at smaller measuring angles. Gained data is subsequently trans-
formed into the equivalent particle diameter (volume based) utilising the Mie or the 
Fraunhofer theory [119]. 
Laser diffraction was applied to determine PSDs of spay-dried and micronised drugs. 
Therefore, a Helium Neon Laser Optical System (HELOS®, Sympatec GmbH, 
Clausthal-Zellerfeld, Germany) was equipped with a RODOS® dry dispersion mod-
ule (Sympatec GmbH) and an R2 lens with a measuring range of 0.25 – 87.5 µm. 
Samples were fed manually to obtain an optical concentration between 1 and 5 %, 
while powders were dispersed towards the measurement chamber by compressed 
air (3 bar). Data evaluation was performed with the Windox 5 software (Sympatec 
GmbH) based on the Fraunhofer Enhanced equation to determine cumulative fre-
quency (Q3) and probability density function (q3*). Additionally, characteristic varia-
bles of the PSD, namely 𝑥10, 𝑥50 and 𝑥90, i.e. the volume based equivalent diameter 
at which 10 %, 50 % or 90 % of particles under investigation are smaller, were pro-
vided. The span value served as a measure for PSD width (equation 10). 
𝑺𝒑𝒂𝒏 =  
𝒙𝟗𝟎−𝒙𝟏𝟎
𝒙𝟓𝟎
   equation 10 
3.4.1.2 Dynamic Image Analysis 
In order to determine size and shape of GBs, particles were analysed using image 
analysis equipment. Here, particles are accelerated in a fall shaft by gravitation, while 
they are dispersed due to particle-wall and particle-particle collisions. A high-speed 
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camera records the particles on up to 450 images/s. This setup allows size determi-
nation between 1 and 20000 µm. 
Measurements were performed with the QICPIC system (Sympatec GmbH) at a re-
cording speed of 300 Hz. For sample dispersion, a VIBRI vibrating chute (Sym-
patec GmbH) was coupled with GRADIS gravity disperser (Sympatec GmbH). On the 
one hand, this provided information about PSDs. On the other hand, images were 
used to determine particle sphericity (𝑆𝑝ℎ) as the measure for overall shape. 𝑆𝑝ℎ is 
defined as the ratio of the perimeter of the equivalent circle (𝑃𝐸𝑄𝑃𝐶) to the real perime-
ter (𝑃𝑟𝑒𝑎𝑙). This is described in equation 11, where 𝐴 is the area of the particle. 
𝑆𝑝ℎ can accept values between 0 and 1, whereby 1 shows a perfect spherical shape. 
𝑺𝒑𝒉 =
𝑷𝑬𝑸𝑷𝑪
𝑷𝒓𝒆𝒂𝒍
=
𝟐√𝝅∗𝑨
𝑷𝒓𝒆𝒂𝒍
  equation 11 
3.4.1.3 Scanning Electron Microscopy 
This method is based on electrons which are emitted by a wolfram cathode and are 
accelerated in an electric field at a high voltage [120]. The created electron beam is 
focused onto the specimen surface via solenoids. Depending on interactions between 
electrons and atoms of sample surface, different signals including the emission of 
secondary electrons are recorded. Hereby, a magnification of up to 500,000-fold can 
be achieved. The process is typically performed under high vacuum to avoid interac-
tions with airborne molecules and atoms. 
All measurements of scanning electron microscopy (SEM) were conducted using a 
Zeiss Ultra 55 Plus (Carl Zeiss NTS GmbH, Oberkochen, Germany) at a working volt-
age of 2kV. Signals were recorded by a SE-2 detector. Since nonconductive samples 
tend to build up electrostatic charge during scanning, samples were fixed onto carbon 
stickers and sputtered with a Bal-Tec SCP 050 Sputter Coater (Leica Instruments, 
Wetzlar, Germany) for 65 s prior to analysis. This ensured electrical conductivity and 
grounding to minimize imaging faults.  
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3.4.1.4 Contact Angle Measurements 
Determination of contact angle (CA) employing the sessile drop method was conduct-
ed to investigate chemical surface properties of different modified GBs. In general, 
water is used as the liquid component in this setup. Therefore a low CA can be asso-
ciated with a hydrophilic surface since increased potential for interaction between the 
surface and the water drop causes spreading of the water drop. This consequently 
decreases the measured angle of contact. 
Experiments were carried out with an OCA 20 contact angle meter (DataPhysics In-
struments GmbH, Filderstadt, Germany) equipped with a USB CCD-camera. A water 
drop of < 1 µl was generated manually and placed onto the GB surface. This proce-
dure was repeated on 20 GBs to calculate the mean CA and StD.  
3.4.1.5 Atomic Force Microscopy 
Surface Topography 
Atomic force microscopy (AFM) is a versatile tool for the characterisation of surface 
properties like morphology, polarity or roughness [121–123]. In contrast to conven-
tional visualisation techniques, AFM generally relies on direct interaction with the 
specimen. The basic setup for surface imaging is illustrated in Figure 3-15. For analy-
sis purposes a cantilever with a sharp tip at the end raster-scans the surface of the 
sample which is fixed onto a piezo-motorised stage. As the tip scans across the spec-
imen surface, present irregularities cause twisting and bending of the cantilever. This 
leads to specific extents and angles of deflection of the laser beam, which is focused 
onto the cantilever. These signals are detected by a photo diode and can be trans-
formed by a processing unit to provide information about surface topography [124]. 
This technique is used to visualize sample surfaces on three-dimensional height im-
ages in a highly detailed fashion even on nano-scale. In addition, it provides the op-
portunity to quantify the degree of surface roughness and therefore allows direct 
comparison of different samples. 
Initially, carrier particles under examination were fixed onto a commercially available 
glass slide using a two-component adhesive (UHU, Buehl, Germany). Carrier imaging 
as well as determination of surface roughness were performed with a NanoWiz-
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ard I (JPK Instruments AG, Berlin, Germany) equipped with an OMCLAC 160 TN-W2 
cantilever (Olympus K.K., Tokyo, Japan). Three areas of 100 µm2 (10 µm x 10 µm) 
each on three different GBs were measured for every type of carrier with tapping 
mode imaging. From gained data, carrier surface roughness, expressed as the root 
mean square roughness (Rrms), was calculated with the help of Gwyddion 2.42 data 
analysis. 
 
Figure 3-15 AFM setup for surface characterisation 
The Rrms was calculated based on equation 12, where 𝑛 is the number of data points 
and 𝑥𝑖 is the vertical distance of the 𝑖
𝑡ℎ data point from the mean value of the corre-
sponding scan line [125]. Due to the sphericity of samples under investigation, the 
overall curvature was taken out of the equation by subtracting from each AFM picture 
before the actual calculation. 
𝑹𝒓𝒎𝒔 =  √
𝟏
𝒏
∑ 𝒙𝒊
𝟐𝒏
𝒊=𝟏    equation 12 
Adhesion Forces 
Colloidal probe AFM was used to investigate AFs between physically modified GBs 
and BUD sd. Here, a tipless cantilever is equipped with a single particle (Figure 3-16) 
which is brought into and out of contact with the specimen surface. The AF is calcu-
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lated from those measurements based on Hooke´s law [126], where 𝑥 and 𝑘 repre-
sent the cantilever displacement induced by interparticle forces and the spring con-
stant, respectively (equation 13). The latter is considered a measure for the cantilever 
stiffness. Since the spring constant is specific for each cantilever, it was determined in 
a preliminary test each time. This method provides the possibility to measure forces 
between an API particle and the carrier surface directly as the AF is equivalent in 
magnitude to the force required to detach the respective particle [127]. 
𝑨𝑭 = 𝒌 ∗ 𝒙    equation 13 
Therefore, a single API particle was glued onto a NSC 12 cantilever (Anfatec Instru-
ments AG, Oelsnitz, Germany) with the help of a NMO-203 micromanipula-
tor (Narishige Group, Tokyo, Japan). Figure 3-16 presents exemplary an SEM picture 
of a prepared cantilever. A grid of 5 x 5 µm was laid on the scan area of the carrier 
resulting in 25 measuring points. On each scan point, the force needed to detach the 
API particle from the carrier surface was monitored 50 times, leading to 1250 force 
curves for a single GB. This procedure was repeated three times with a new set of 
API and carrier for every type of GB. Mean values and standard deviations were cal-
culated based on AFs determined on the total of 75 measuring points for every type of 
GB. Measurements were conducted with a JPK NanoWizard I as well. Force curves 
of adhesion were evaluated using a self-written LabVIEW program developed by 
Dr. Michael Kappl (Max Planck Institute for Polymer Research, Mainz, Germany). 
 
Figure 3-16 Exemplary SEM micrograph of a spherical glass particle attached to an 
AFM cantilever taken from [128] 
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3.4.1.6 Density Measurements 
Gas pycnometry was used to investigate the density of spay-dried powders. For its 
characterisation, the volume of inert gas displaced by the sample is measured. As this 
equals the sample volume, the density can be calculated by implementing the sample 
weight [129]. Generally, helium is used as inert gas since it is able to permeate in 
small pores up to a minimal diameter of 2 Å. Hereby the volume of open pores on the 
surface can be taken into account, while closed pores remain unrecognised.   
Density of samples was measured with a Pycnomatic ATC helium pycnometer (Poro-
tec, Hofheim, Germany). For this, the measuring vessel was filled up to about 80 % 
with the sample powder, carefully placed inside the instrument and analysed in 
10 cycles. 
3.4.1.7 Dynamic Vapour Sorption 
The measuring principle is based on absorption and desorption processes of solvents 
at defined rH [130]. Since amorphous materials are characterised by a higher poten-
tial to absorb moisture compared to those in the crystalline state and since recrystalli-
sation is accompanied by water loss, transitions from amorphous to crystalline state, 
inter alia, can be investigated [131]. Hence, DVS was used as an additional method of 
characterisation for the different APIs. Findings also contributed to define optimal am-
bient conditions for blending and impaction analysis in order to avoid recrystallisation 
of spray-dried APIs.  
DVS measurements were carried out using a DVS-HT (Surface Measurement Sys-
tems Ltd., London, UK) applying the following method under isothermal condi-
tions (25 °C): 
Step 1: Increase of rH from 0.0 to 0.9 followed by decrease to 0.0 again 
Step 2: Repetition of step 1 
After reaching equilibrium, where no significant change in mass (< 0.0005 %/min) was 
noticed, rH was increased or decreased by 0.1 to the next stage. 
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3.4.1.8 X-Ray Powder Diffraction 
X-ray powder diffraction (XRPD) is commonly used for characterising the degree of 
crystallinity and identifying crystal polymorphs. Here, X-rays are generated in a tube 
by a cathode while electrons are accelerated towards the anode and in direction of 
the sample by applying high voltage. Diffraction of X-rays from probe atoms can be 
detected and processed into diffraction patterns that provide information about the 
crystal structure. Amorphous samples do not lead to distinct diffraction patterns, but 
only create background signalling (halo), hence, this technique was used in the pre-
sent work to check for amorphicity.  
Powder examination was performed by XRPD (Stadi P diffractometer, Stoe & Cie 
GmbH, Darmstadt, Germany). An operating voltage of 40 k V was applied and meas-
uring range was set to θ = 8 – 35° with a step rate of 2θ = 0.05°. 
3.4.1.9 Inverse Gas Chromatography 
Inverse gas chromatography (iGC) is a versatile technique to investigate physico-
chemical properties of various materials. Contrary to conventional gas chromatog-
raphy, the probe under investigation is filled into a chromatographic column to provide 
the stationary phase (Figure 3-17). Different alkanes varying in their chain length are 
injected as mobile phase into the probe-packed column at a constant carrier gas flow 
rate [132]. As retention time of the eluents (detected by a flame ionisation detec-
tor (FID)) is, amongst other factors, highly dependent on potential for interaction be-
tween eluents and sample molecules, gained data serves for further characterisation 
of surface and bulk properties [133]. 
The dispersive part of surface energy (γs
d) and γs
d profiles were investigated with an 
SMS Inverse Gas Chromatograph (Surface Measurement Systems Ltd., London, UK). 
For analysis, about 0.2 g of API or 4.5 g of GBs were filled into silanised glass col-
umns (Surface Measurement Systems, 300 mm x 6 mm outer diameter) with an inner 
diameter of 3 or 4 mm, respectively and sealed with silanised glass wool. After a pre-
compaction step of 10 minutes utilising the column-packing accessory (Surface 
Measurement Systems) samples were initially equilibrated at 303 K and 0 %rH for two 
hours to ensure a comparable state of the samples. For examination of γs
d, al-
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kanes (hexane, heptane, octane, nonane, decane) were injected at infinite dilu-
tion (0.03 p/p0), while methane (0.01 p/p0) was used to determine the dead volume. 
Calculation of γs
d from gained data was performed with the help of the iGC Advanced 
Analysis Macro V1.41 (Surface Measurement Systems) using Microsoft Excel 2010. 
A profound overview of applied arithmetic operations can be taken from [134]. 
To compile γs
d distribution profiles, the appropriate alkanes were injected at different 
concentrations ranging from 0.03 to 0.95 p/p0. By doing so, isotherms for each alkane 
were created to subsequently acquire information of surface energy profiles of the 
specimen [135,136]. Again, methane was used to identify the dead space volume. 
Data was evaluated with SMS Isotherm Macros Version 1.4 Advanced and Microsoft 
Excel 2010. 
 
Figure 3-17 Setup of the iGC Instrument 
3.4.1.10 Powder Rheometry 
The purpose of these measurements is the investigation of powder properties of prac-
tical relevance, i.e. fluidization, flowability, cohesiveness and compressibility. Fur-
thermore, it provides the possibility to examine interactions between pharmaceutical 
powders and different materials facilitating the choice of powder processing equip-
ment. 
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Basic Flowability Energy 
Basic flowability energy (BFE) is an important criterion for flow properties of powder 
samples. In general, a high value for BFE can be considered as a sign for suboptimal 
flowability. However, is it also influenced by particle properties, namely size, shape 
and morphology and additionally by powder compressibility [137]. 
In a first step, a conditioning cycle is applied to ensure a comparable state of the 
sample in terms of packing density. Afterwards, the twisted blade (A) performs a 
downward traverse while rotating anticlockwise at a tip speed of 100 mm/s through 
the test vessel (B) (Figure 3-18). The BFE can be calculated from the work required to 
move the blade from top to bottom of the vessel. 
 
Figure 3-18 Schematic setup for the BFE test 
Wall Friction 
This setup is used to investigate interactions between the sample and wall material, 
e.g. different modified GBs and the inhaler wall in this study. The vessel is filled with 
sample material which is brought into contact with a disc mounted onto the wall fric-
tion piston. A normal stress is applied by the piston and the energy required for rota-
tion of the disc is recorded [138]. 
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For the determination of the wall friction angle (WFA), the measurement piston was 
equipped with a plate in appropriate size and of the same material as the inhalation 
device. By monitoring the energy, which was required to move the plate across the 
sample surface, the kinematic WFA was quantified. Calculations are based on equa-
tion 14, where τ𝑥 and σ𝑥  are the shear stress and the normal stress on the wall mate-
rial, respectively. 
𝑾𝑭𝑨 =  𝒕𝒂𝒏−𝟏 ∗ (
𝝉𝒙
𝝈𝒙
)  equation 14 
In the present study all measurements were conducted using a FT4 Powder Rheome-
ter® (Freeman Technology, Tewkesbury, UK). It provides various methods to charac-
terise powder behaviour under different conditions [139], whereby those methods can 
be tailored to the user´s need.  
3.4.2 Characterisation of Interactive Mixtures and in vitro Deposition 
3.4.2.1 Evaluation of Drug Content 
The content of each API in its respective mixture was determined by reversed-phase 
high performance liquid chromatography (RP-HPLC) with a Waters HPLC sys-
tem (Waters Corporation, Milford, USA) equipped with the appropriate column (sec-
tion 3.4.2.1). Standard solutions of the respective drug in concentrations 
from 1 µg/µL to 100 µg/µL provided the calibration curve. The injection volume was 
set to 100 µl and each standard solution was analysed in duplicate. Detailed infor-
mation about HPLC methods are listed in section 8.1. 
3.4.2.2 Determination of Content Uniformity 
After blending, the interactive mixture was spread over a sheet of paper (Din A4) and 
10 samples of 150 mg ± 10 % each were taken from different spots to receive repre-
sentative information about blend homogeneity. Samples were dissolved in the ap-
propriate solvent and analysed via HPLC analysis. Only interactive mixtures with a 
coefficient of variation (relative standard deviation, rStD) of < 5 % were used for fur-
ther experiments.  
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3.4.2.3 Impaction Analysis  
Impaction analysis is the method of choice for in vitro testing of aerodynamic perfor-
mance of preparations for inhalation. It needs to be noted that an impactor cannot be 
seen as an artificial lung model due to e.g. lack of possibilities to display physiological 
conditions in the human lung [140]. However, it can be used to determine the aerody-
namic particle size distribution (APSD). Since particles are separated due to gravita-
tional forces in this setup, the aerodynamic particle size is influenced by particle 
shape and mass.  
 
 
Figure 3-19 Setup of a closed NGI equipped with Induction Port and Preseparator (top) 
and an open NGI with collection cups and the MOC (bottom) 
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The Next Generation Pharmaceutical Impactor (NGI), described as Apparatus E in 
the Ph. Eur. [106], was used to investigate APSDs (Figure 3-19). Therefore, each of 
the seven stages, the micro-orifice collector (MOC) and the impaction plate of the 
preseparator were coated with stage coating consisting of ethanol (51 %), glycer-
ol (34 %) and Brij® 35 (15 %) and allowed to dry completely. By that, a potential erro-
neous deposition profile caused by particles bouncing off the stages was prevented. 
250 mg of blend under investigation were filled into hard gelatine capsules size 3 with 
a spatula. Prior to impaction analysis, capsules and inhalation device were deionised 
with a Static Line LC discharging bar (HAUG GmbH & Co. KG, Leinfelden, Germany) 
to minimize electrostatic charging. When using interactive mixtures with CSCs of 
100 % or 50 %, three capsules were used for each NGI run. Investigations concerning 
blends with a CSC of 25 % made it necessary to release the content of five capsules 
to guarantee quantifiable amount of drug across the whole impactor. After inhalation 
manoeuvre, the device was rinsed with 20.0 mL of the appropriate solvent (sec-
tion 8.1) followed by washing of capsule shells with this solution on orbital shak-
er 3005 (Gesellschaft für Labortechnik GmbH, Burgwedel, Germany) for one minute. 
Drug located in the induction port including mouthpiece and preseparator was dis-
solved with 15.0 mL and 30.0 mL, respectively. Stages and MOC were rinsed with 
5.0 mL each. Drug content was quantified via HPLC analysis.  
Table 3-7 Overview of parameters for the implementation of aerodynamic assessment 
with different inhalation devices 
Inhalation device Flow rate, L/min Valve opening time, s 
Cyclohaler 100 2.4 
 
  Unihaler & Modular Inhaler 60 4.0 
 
The appropriate flow rate for the used inhaler (Table 3-7) was adjusted with the help 
of a digital flowmeter DFM3 (Copley Scientific Ltd., Nottingham, UK) to obtain a pres-
sure drop of 4 kPa across the inhalation device as required by the Ph. Eur. [106]. 
Valve opening time was set in respect to the corresponding flow rate to obtain an in-
haled volume of 4 L. This is considered as the average lung volume of an adult. Data 
evaluation was performed with the Copley Inhaler Testing Data Analysis Soft-
ware 3.0 (Copley Scientific Ltd.). Hereby, delivered dose (DD) in µg signifies the 
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amount of API recovered from the entire NGI (induction port, preseparator, stages 
and MOC). Additionally, the mass median aerodynamic diameter (MMAD) was de-
fined as the aerodynamic diameter at which 50 % of the particles are larger with re-
gard to mass [141]. Fine particle dose (FPD) in µg and fine particle fraction (FPF) 
in %, being the amount of drug with an aerodynamic diameter < 5 µm and the fraction 
of API < 5 µm in proportion to the DD, respectively, were utilised to evaluate aerody-
namic performance of interactive mixtures (equation 15).         
Capsule retention (𝐶𝑅) in % was calculated based on equation 16, where 𝑤𝑐𝑎𝑝𝑠𝑢𝑙𝑒 is 
the amount of drug found in the capsules and 𝑅𝐷 is the recovered dose, defined as 
the total mass of API recovered from the impactor plus the fraction recovered from the 
capsule. 
𝑭𝑷𝑭 =  
𝑭𝑷𝑫
𝑫𝑫
∗ 𝟏𝟎𝟎 %  equation 15 
𝑪𝑹 =  
𝒘𝒄𝒂𝒑𝒔𝒖𝒍𝒆
𝑹𝑫
   equation 16 
3.4.2.4 Determination of Specific Device Resistance  
 
Figure 3-20 Exemplary illustration of the mathematical determination of SDR 
Specific device resistance (SDR) can be used to compare resistance behaviour of 
different inhalation devices. Investigations were conducted implementing a method 
based on the setup for determination of delivered dose uniformity. As a first step, the 
resulting pressure drops within the inhaler at adjusted flow rates (20 – 100 L/min) 
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were measured. By plotting flow rate against square root of the corresponding pres-
sure drop, SDR in kPa0.5*min/L resulted from the slope of the regression line [142]. 
Consequently, the steeper the slope, the higher the resistance of the inhaler is. Figure 
3-20 presents a resulting graph in exemplary manner. 
Air flow was generated by a HCP5 vacuum pump (Copley Scientific Ltd) and pressure 
drops and flow rates were measured with a Critical Flow Controller Model TPK (Cop-
ley Scientific Ltd.) and Flow Meter Model DFM2 (Copley Scientific Ltd.), respectively. 
3.4.2.5 Calculation of True Surface Coverage 
 
Figure 3-21 Applied methodology for the determination of TSC 
The effective drug loading, expressed as TSC in this study was determined based on 
data from impaction analysis. As a first step, RD was quantified for the respective NGI 
experiments via HPLC. By knowing the initial mass of interactive mixture in the cap-
sules, the amount of API was extrapolated to the total mass of blend. Dividing this 
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mass by the original net weight of API provided TSC for the respective blend. Figure 
3-21 gives an illustration of calculation steps for TSC.  
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4 Results and Discussion  
4.1 Spray Drying of Different APIs 
For the present study, drug particles with certain properties such as the suitable size 
range for inhalation, uniformity and a spherical shape were needed. As described in 
section 3.3.4, interactive blends should be prepared by utilising the exact amount of 
API to cover a certain percentage of the total carrier surface. However, calculations 
require both carrier and API in a spherical shape. SD was chosen as the appropriate 
technique to produce micron-sized particles with the desired characteristics for dry 
powder inhalation. Its main advantage is the ability to alter process parameters to de-
termine product properties, e.g. size, shape and morphology [143]. Previous studies 
have reported the feasibility of obtaining a size range of 1 to 5 µm by SD [144,145]. In 
general, the product is also characterised by a narrow size distribution which is bene-
ficial to achieve an enhanced respirable fraction [146]. Moreover, the particles were 
usually of spherical shape when processing starting material in solution [109,147].  
Within the DoEs, the impact of factors on particle size (x50) and width of the 
PSD (span value) was examined to subsequently select optimal SD conditions to 
meet product requirements mentioned above (PSD, shape). An efficient process is 
also desired, wherefore the product yield, defined as the relation between initial mass 
weighed in and product mass, was determined. Based on preliminary trials, constant 
and varying parameters as well as their range were selected for the respective DoE 
setups. Drying gas was kept at a maximum flow rate of 40 m³/h for all experiments to 
obtain products with minimum residual moisture. Increased gas velocity within the 
spray dryer is also known to trigger major collection and separation efficiency of the 
cyclone [143]. Since the present study aimed at elucidating the influence of carrier 
surface characteristics for a wide range of drugs, BUD, FF and TB with extensively 
differing chemical properties were chosen.  
Hereafter, DoEs and their outcome for the three APIs are subsequently discussed 
followed by characterisation of the final products which were utilised to manufacture 
interactive mixtures. However, only valid and significant models are presented. De-
tailed information about the different DoE setups can be taken from section 8.5. 
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4.1.1 Budesonide 
For the first DoE, preliminary trials suggested the variation of inlet temperature (Tinlet, 
80 – 120 °C), feed rate (FR, 3.2 – 5.4 mL/min) and feed concentration (FC, 4 – 10 %) 
at a constant spray gas flow (SGF, 414 L/h) within the given ranges. Particle size of 
BUD was solely influenced by the FC, while x50 values varied from 1.2 ± 0.0 µm 
to 3.3 ± 0.1 µm, as seen in Figure 4-1. For yield and span value, no significant models 
could be established. 
 
Figure 4-1 Contour plot of the mean particle size for BUD as a response of the factors 
FC on the x-axis and InT on the y-axis 
FC had a significant effect on particle size as the increase of the FC by 3 % induced a 
size increase of 0.75 ± 0.08 µm. During SD, each atomised droplet forms one particle. 
By increasing the solid concentration, an extended amount of drug molecules will be 
present in each droplet. As the solvent gets evaporated, a larger particle forms com-
pared to a solution with a lower drug concentration. This effect has also been de-
scribed for a range of other substances [148,149].   
Based on gained data, optimal process parameters were predicted using the MODDE 
software as well. Since particle size was the only response where a significant model 
was established and it was merely affected by FC, the following equation could be 
applied which is derived from the general equation 5 (section 3.2.1): 
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𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑠𝑖𝑧𝑒 = 𝑐0 + 𝑐1𝐹𝐶 
This suggested a FC of 10 % to manufacture the final product for further investiga-
tions. As the x50 value was found to be independent of FR and Tinlet, these factors 
were minimised to 3.2 mL/min and maximised to 120 °C, respectively, for the final 
product to evaporate most of the solvent present in the respective atomised drops 
and maintain a dry powder.  
4.1.2 Formoterol Fumarate 
Here, FC (2.5 – 7.5 %), FR (2.1 – 4.3 mL/min) and SGF (334 – 426 L/h) were altered 
at a constant Tinlet of 100 °C based on preliminary trials. Particle size was significantly 
governed by concentration and gas flow in a positive and negative manner, respec-
tively (Figure 4-2). The process resulted in x50 values between 1.0 ± 0.0 µm and 
4.3 ± 0.2 µm. Significant models were also established for product yield and span 
value. A linear term (positive) as well as a quadratic correlation (negative) of the con-
centration was shown for the yield. It was also affected in a negative way by the gas 
flow (Figure 4-3). Span value was governed FC (positively). Here the SGF showed a 
linear term as well as a quadratic correlation (both negative) (Figure 4-4). 
 
Figure 4-2 Contour plot of the particle size for FF as a response of the factors FC on 
the x-axis and SGF on the y-axis 
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The influence of FC on particle size has been discussed earlier. For the SGF, a nega-
tive correlation was determined. An increase of gas flow supplies more energy to the 
nozzle which forces a smaller diameter of atomised droplets [148]. In consequence, 
less drug molecules are present in a single droplet resulting in smaller particles.  
Product yield was, inter alia, determined by the SGF as well. In general, a low flow 
rate led to superior API recovery from the process while increasing flow reduced 
product yield. When the SGF is increased, a considerable amount of spray-dried par-
ticles will be of comparatively low size < 0.5 µm due to the small droplet size at these 
conditions. This fraction is separated from the airstream by the cyclone with only mi-
nor efficiency. Therefore, a certain amount of particles within this size range remains 
in the airstream and will be carried out of the system. Consequently, this fraction does 
not add to the powder collected in the product vessel forcing an insufficient yield. Sim-
ilar considerations apply to the impact of API concentration. Initially, product yield in-
creases with FC since larger particles are produced which can be separated more 
easily. At higher API concentrations, a certain percentage of particles has a larger 
diameter and is partly collected in the primary separation flask on the bottom of the 
drying chamber and therefore does not contribute to the final yield. 
 
Figure 4-3 Contour plot of the product yield for FF as a response of the factors FC on 
the x-axis and SGF on the y-axis 
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The increase of SGF triggered a narrow PSD, since overall smaller particles were 
produced. The majority of larger particles got separated from the collected product 
which was therefore characterised by a lower span value. Furthermore, an enhanced 
API concentration generally lowered the efficiency of the SD process and led to over-
all larger particles simultaneously limiting the fraction of < 0.5 µm.   
 
Figure 4-4 Contour plot of the span value for FF as a response of the factors FC on the 
x-axis and SGF on the y-axis 
As significant model could be shown for particle size, yield and span value (with the 
significant factors mentioned above), SD conditions were optimised based on equa-
tions describing these conditions: 
𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑠𝑖𝑧𝑒 = 𝑐0 + 𝑐1𝐹𝐶 + 𝑐2𝑆𝐺𝐹 
𝑌𝑖𝑒𝑙𝑑 = 𝑐0 + 𝑐1𝐹𝐶 + 𝑐2𝑆𝐺𝐹 + 𝑐4𝐹𝐶
2 
𝑆𝑝𝑎𝑛 = 𝑐0 + 𝑐1𝐹𝐶 + 𝑐2𝑆𝐺𝐹 + 𝑐5𝑆𝐺𝐹
2 
Consequently, concentration was set to 4.5 %, while FR and SGF were fixed at 
2.1 mL/min and 357 L/h, respectively. Additionally, a Tinlet of 120 °C was applied to 
minimise residual moisture in the final product.  
Results and Discussion 
 
58 
 
4.1.3 Tiotropium Bromide 
Implementing findings from preliminary trials, SD experiments for the hydrophilic 
model drug TB employed a variation of FC (2.0 – 4.0 %), Tinlet (120 –150 °C) and 
SGF (380 – 496 L/h). FR was adjusted to 3.7 mL/min for all experiments. By doing so, 
a valid model was established concerning the mean size (Figure 4-5). Again, concen-
tration and gas flow had a significant impact. An interaction of the two was also ob-
served leading to a mean particle size of 1.9 ± 0.0 µm – 4.85 ± 0.1 µm. 
 
Figure 4-5 Contour plot of the particle size for TB as a response of the factors FC on 
the x-axis and SGF on the y-axis 
For TB, a significant model was established for particle size and consequently optimal 
parameters were determined from the following equation: 
𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑠𝑖𝑧𝑒 = 𝑐0 + 𝑐1𝐹𝐶 + 𝑐2𝑆𝐺𝐹 + 𝑐7𝐹𝐶𝑆𝐺𝐹 
This suggested an API concentration of 4 % and a SGF of 451 L/h. Tinlet was set to 
150 °C and FR to 3.7 mL/min.  
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4.1.4 Characterisation of the Final Products 
After the SD process, drug powders were characterised by different measurement 
techniques to understand their physico-chemical properties (Table 4-1). In the course 
of this, particle size, span value and 𝛾𝑠
𝑑 were of particular interest. In addition, bulk 
properties were investigated. Density of the powder samples was determined, since it 
was needed for calculations of CSC. Samples were also subjected to XRPD to inves-
tigate the crystallinity. Examination of sorption behaviour was performed to receive 
information about sample stability and hygroscopicity. 
Although a slight batch to batch variability of the spray-dried products was experi-
enced in terms of particle size and span value due to the manufacturing process, e.g. 
minor fluctuations in drying gas pressure, other properties remained constant. For that 
reason, the following chapter representatively displays examination of batches of 
spray-dried APIs utilised for experiments to study the impact of chemical surface 
properties of the carrier described in section 4.2.    
Table 4-1 Summary of physico-chemical properties and StDs of spray-dried APIs uti-
lised for the manufacturing of interactive mixtures (n=3) 
API x50, µm Span value Density, kg/m³  γs
d, mJ/m² 
BUD 2.9 ± 0.1 2.4 ± 0.0 1250 ± 10 48.5 ± 0.3 
     
FF 2.7 ± 0.1 2.1 ± 0.1 1720 ± 10 34.0 ± 0.6 
     
TB 2.7 ± 0.1 2.0 ± 0.0 1730 ± 20 48.1 ± 0.9 
 
4.1.4.1 Particle Size   
These investigations were performed via laser diffraction. Size is a critical parameter 
of inhaled particles since it determines region particle deposition within the respiratory 
tract during inhalation (in interplay with density and shape).  
FF and TB showed x50 values of 2.7 ± 0.1 µm each and narrow PSDs of 2.1 and 
2.0, respectively. The latter can be linked to a largely monomodal size distribution for 
both APIs. Mean particle size of BUD was determined to be marginally larg-
Results and Discussion 
 
60 
 
er (2.9 ± 0.1 µm) with a span value of 2.4. This is shown by the PSD curves display-
ing a slightly bimodal distribution for the hydrophobic model drug (Figure 4-6). 
 
Figure 4-6 PSDs (+StD) with logarithmic scaling on the x-axis of BUD, FF, and TB (n=3) 
4.1.4.2 Particle Shape and Morphology 
Apart from size, drug shape was examined via SEM. SD is known to produce round 
particles which is also true for BUD, FF and TB (Figure 4-7). For BUD, two particle 
populations of about > 2 µm and of about < 1 µm were observed. This is in agreement 
with its slightly bimodal PSD described earlier. On the contrary, FF and TB particles 
were found to be more evenly distributed and a major quantity of particles was in the 
range of 2.0 to 3.5 µm.  
As further displayed in Figure 4-7, BUD sd and FF sd were characterised by a smooth 
surface without any irregularities. SD of TB led to a limited amount of microscopic in-
dentations on some particles > 2.5 µm. In literature, drying rate, viscosity and surface 
tension of the solvent were described to govern morphology of spray-dried amor-
phous substances [150]. Nevertheless, the overall spherical shape was maintained 
and no indentations were present on particles < 2.5 µm.  
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Figure 4-7 SEM micrographs of spray-dried APIs at respective magnifications of 
1000x (top) and 5000x (bottom) 
The overall smooth surface of the APIs ensured a defined and comparable contact 
area between drug particles and the carrier within interactive mixtures investigated in 
the following.  
As shown in the present chapter, widely different SD conditions were needed to main-
tain particles of the three APIs with comparable properties such as size, morphology 
and shape. This can partly be ascribed to the used solvents. BUD and FF were pro-
cessed in organic solvents which show a comparatively low surface tension. This was 
described to alter particle morphology and also decrease particle size [151]. It conclu-
sively explains why an overall lower FC and SGF had to be employed for TB which 
was dissolved in ddH2O compared to BUD and FF. In addition, particle size and PSD 
were also found to be influenced by the drying temperature. That had to be adjusted 
in the present study due to the different solvents used for the APIs [152]. Another fac-
tor potentially influencing material characteristics of the spray-dried product is the type 
of drying gas, while nitrogen or compressed air were used for processing of BUD,FF 
or TB [153]. The extent to which these factors influence the product, however, is high-
ly dependent on material characteristics of the raw material and is oftentimes difficult 
to predict [154]. 
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4.1.4.3 Stability and the Impact of Ambient Conditions 
With the help of XRPD and DVS measurements, crystallinity and moisture sorption 
isotherms were evaluated in order to estimate stability of the spray-dried drugs and to 
determine optimal ambient conditions for sample handling and impaction analysis. 
The importance of drug stability on aerodynamic performance has been emphasised 
in literature before. An occurring recrystallisation within the interactive mixture was 
shown to trigger intraparticle solid-bridging [155]. Furthermore, a control of tempera-
ture and rH is mandatory as liquid bridges form under certain conditions as result of 
an interparticle moisture condensation [156]. The consequent rise of capillary forces 
extents interactions between carrier and API. This impedes drug detachment. 
XRPD diffractograms of the three spray-dried APIs are depicted in Figure 4-8, pre-
senting the absence of a specific diffraction pattern, which would indicate crystalline 
regions. Instead, samples exhibited so-called halos linked to background signalling. 
This suggests amorphicity after the SD process. 
 
Figure 4-8 XRPD diffractograms of spray-dried APIs 
The behaviour of the fully amorphous samples under different relative humidities was 
examined via DVS in a two cycle program (0 – 90 – 0 %rH each) with water (sec-
tion 3.4.1.7). In general, samples in the crystalline state show a largely different mois-
ture uptake compared to amorphous materials [157]. Additionally, recrystallisation is 
accompanied by a rapid water loss of the specimen which enables the identification of 
state changes occurring at certain ambient conditions [158]. 
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Mass of all samples increased steadily when raising the rH up to 90 % (Figure 4-9). 
BUD displayed the lowest mass change of + 4.7 %. Sorption isotherms of the two se-
quent cycles showed no significant difference. For FF, a mass increase of 12.9 % was 
detected, while a rapid mass loss becomes apparent at 90 %rH. The second cycle 
induced solely a negligible water uptake. As far as TB is concerned, an accelerated 
moisture sorption was observed up to an increase in mass of 8.1 %. At 70 %rH, a 
sudden decrease in mass occurred. When further lowering the rH, initial mass was 
reached again. The second cycle only induced a mass increase of 3.0 %. 
 
Figure 4-9 Absorption behaviour of spray-dried BUD, FF and TB when subjected to a 
two cycle DVS program (0 – 90 % rH) with water 
The behaviour of FF during analysis indicates a recrystallisation event, underlined by 
the abrupt mass change in the first cycle. Amorphous, hydrophilic materials are 
known to adsorb water at their surface [159]. Unlike crystalline materials, they addi-
tionally tend to absorb water inside the particles forcing a higher moisture up-
take [160]. Due to the ability of water to act as a plasticiser, this increases molecular 
mobility within the particles ultimately inducing recrystallisation [161]. During this pro-
cess, a major loss of water occurs. As a consequence, sorption behaviour of FF dur-
ing the second cycle significantly differs from the first one as a result of the recrystalli-
sation. Similar observations were made when examining TB, where a recrystallisation 
event could be detected at a rH of 70 %. This is supported by a diminished increase 
in mass during the second cycle. Here, hygroscopic nature of TB becomes also ap-
parent as an uptake of water of 3.2 % was observed compared to only 1.1 % for the 
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recrystallised FF. Hydrophobic BUD presented lower overall affinity towards water 
vapour compared to the hydrophilic model drugs. Neither recrystallisation nor a differ-
ent behaviour was observed during or between the two sorption cycles underlining the 
stability of BUD sd at a moderate temperature of 25 °C. 
Moreover, it can be taken from Figure 4-9 that absorption and desorption of vapour as 
well as the release of water happened at a different pace for the three APIs. This 
could be monitored due to the experimental setup. Only after reaching equilibrium of 
the sample (< 0.005 %/min change in mass) the next step within the two-cycle pro-
gram was initiated.  
Based on these findings, optimal ambient conditions for material processing and im-
paction analysis were defined. BUD showed extended stability regardless of the rH 
and therefore moderate conditions of 21 °C and 45 %rH were chosen to mainly en-
sure a comparable experimental setting. FF and TB displayed recrystallisation events 
at elevated humidity, which is why rH was set to 30 % and 20 %, respectively at 
standard 21 °C to guarantee maintaining of the amorphous state.  
4.1.4.4 Dispersive Surface Energy 
The dispersive part of the surface energy was examined in order to receive infor-
mation about the extent of non-polar interactions potentially formed between carrier 
and API.  
As displayed in Figure 4-10, energies of 48.5 ± 0.3 mJ/m² and 48.1 ± 0.9 mJ/m² were 
determined for hydrophobic BUD and hydrophilic TB in spray-dried condition, respec-
tively. FF showed a γs
d of 34.0 ± 0.6 mJ/m².  
Despite extensively different chemical properties, solely marginal differences in γs
d 
were experienced for spray-dried BUD and TB, while fairly hydrophilic FF was charac-
terised by reduced interactions with the aliphatic eluents. In consequence, no clear 
correlation between API chemistry and surface energy could be established. In gen-
eral, the γs
d was always higher for the micronised material. This can be attributed to 
the high energy input of the micronisation process leading to particles with an in-
creased surface energy. 
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Figure 4-10 Dispersive surface energies (+StD) of different APIs in spray-dried (black 
bars) and micronised form (grey bars) (n=3) 
It needs to be noted that the γs
d merely displays the dispersive or non-polar surface 
energy which is exhibited by any material. For polar probes, the so-called polar part 
also contributes to the total surface energy and displays interactions such as hydro-
gen bonding or acid-base forces [134]. This especially applies to FF and TB in the 
present study. Consequently surface energies for these APIs could not be completely 
described with the used technique as the iGC instrument did not allow the determina-
tion of those forces. Nevertheless, dispersive surface energy is generally considered 
as a valuable parameter to assess properties of pharmaceutical powders [162]. Thus, 
results from iGC experiments were employed to further characterise the spray-dried 
APIs in this thesis. 
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4.2 Chemical Modification of Glass Beads 
As already pointed out (section 2.3.3.2), very little research has been made on the 
importance of chemical properties of carrier and API for the performance of interactive 
powder blends for inhalation. To examine this scientific question, GBs were incubated 
with different silanes which varied in their functional groups, in three concentrations 
of 0.5 M (1), 0.05 M (2) or 0.005 M (3). This aimed at creating a broad range of hy-
drophobicity on the carrier surface. The effect of the silanisation process was deter-
mined by CA measurements and by iGC to subsequently select four different types of 
modified GBs exhibiting a range of different surface characteristics. Other material 
properties, i.e. flow properties as well as particle size and shape were examined to 
ensure that no significant changes in those had occurred. Hereby, observed effects of 
chemical modification on the TSC and aerodynamic performance could be directly 
correlated to the determined carrier characteristics. Chosen carriers were blended 
with three different APIs differing in chemical properties for their part, namely hydro-
phobic BUD (sd), FF (sd) and hydrophilic TB (sd). In order to find optimal blending 
parameters for the APIs, preliminary trials were conducted with varying blending con-
ditions. Qualities of the blends were determined by content uniformity (section 3.3.5) 
to evaluate homogeneity and also by visual examination of SEM micrographs to as-
sure the integrity of spherical API particles. 
4.2.1 Characterisation of Glass Beads 
4.2.1.1 Contact Angle 
CA measurements were implemented as one technique to characterise carrier prop-
erties before and after modification. It allowed direct determination of hydrophilici-
ty/hydrophobicity through the angle measured between a water drop and the respec-
tive surfaces. The silanisation process generally led to increased CAs compared to 
GB_UT (Table 4-2). Except for FPTS and CTMS, the CA increased with higher con-
centrations of the respective silanes. Additionally, highest overall CAs were found for 
TPCS among all GBs. 
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Table 4-2 Measured CAs of GB_UT and GBs incubated with silanes in different concen-
trations of 0.5 M (1), 0.05 M (2) and 0.005 M (3); LogP values of the silanes were deter-
mined based on mathematical operations described by Wildman et al. [163] (n=20) 
Modification Contact angle, ° Standard deviation, ° LogP value 
GB_UT 24.0 4.9 / 
    
FPTS_1 58.3 6.2 2.00 
FPTS_2 67.8 3.5 2.00 
FPTS_3 47.3 6.6 2.00 
    
CTMS_1 73.8 5.1 2.27 
CTMS_2 40.6 7.2 2.27 
CTMS_3 44.4 13.7 2.27 
    
CDMPS_1 75.6 5.7 2.34 
CDMPS_2 49.5 9.0 2.34 
CDMPS_3 32.4 8.2 2.34 
    
CDPMS_1 80.3 3.2 2.72 
CDPMS_2 54.0 5.9 2.72 
CDPMS_3 49.2 12.9 2.72 
   
 
TPCS_1 86.1 3.1 2.89 
TPCS_2 66.8 6.8 2.89 
TPCS_3 41.2 8.1 2.89 
 
In general, a low CA indicates a hydrophilic specimen as the water drop spreads 
widely on the surface in that case. The low CA of GB_UT can be explained by the 
presence of free silanol groups that confer polarity to the surface. Thus, GB_UT can 
be considered as most hydrophilic carrier in the present study. During incubation, a 
chemical reaction covalently binds silanes to the GB surface (Figure 4-11). Character-
istics of the so-altered surface can be attributed to functional groups of the respective 
silanes which correspond well to their respective logP values (Table 4-2). Conse-
quently, particles treated with rather hydrophilic FPTS showed comparatively low CAs 
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among the modified GBs. Hydrophobicity was enhanced by replacing methyl groups 
of the silanes by more hydrophobic phenyl groups leading to highest CA for GBs 
treated with TPCS. These GBs also exhibited the highest logP value. However, this is 
only true for the highest concentrations (0.5 M). Here, the major part of the carrier 
surface reacted with silanes in solution. Lowering the silane concentration diminished 
the amount of silane molecules available which in consequence decelerated the 
chemical reaction. The total number of molecules might also not have been high 
enough to saturate the free silanol groups on GB surfaces in the first place. To con-
clude, the resulting chemical characteristics of GBs were governed by the silane itself 
and by its concentration as well. When evaluating present results, it needs to be not-
ed that the determination of CA was originally designed for larger and flat surfaces, 
where the respective angles can be measured with the naked eye in a satisfactory 
manner. As GBs are round and only about 500 µm in diameter, measurements are 
presumably not as precise as conventional ones, e.g. on compressed powder. This 
also justifies extended standard deviations of the measurements. 
 
Figure 4-11 Schematic illustration of the silanisation process on GB surfaces adapted 
from Taglietti et al. [164] 
4.2.1.2 Surface Energy 
iGC served as the second technique of surface characterisation. It enabled the exam-
ination of unmodified and chemically modified GBs in regard to surface energy which 
arises from acid-base interactions and nonspecific van-der-Waal forces [165]. The 
latter were of particular interest for GB where hydrophobicity has been increased and 
were examined by determination of γs
d. This was done by injecting a homologous se-
ries of alkanes at infinite dilution. Under these conditions solute molecules (decane, 
nonane, octane, heptane and hexane) solely cover < 1 % of the sample surface. Ta-
ble 4-3 displays γs
d ranging from 28.0 ± 1.0 to 79.4 ± 1.5 mJ/m² for silanised GBs. 
Analysis of GB_UT gave an intermediate γs
d of 42.7 ± 1.6 mJ/m². Results generally 
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illustrate lower energies at higher silane concentration which applies to each modifica-
tion.  
Table 4-3 Dispersive surface energies of untreated and GBs incubated with silanes in 
different concentrations of 0.5 M (1), 0.05 M (2) and 0.005 M (3).  
Modification 
Dispersive surface energy, 
mJ/m² 
Standard deviation, 
mJ/m² 
GB_UT 42.7 1.6 
   
FPTS_1 28.0 1.0 
FPTS_2 54.3 0.7 
FPTS_3 /* 
 
   
CTMS_1 61.3 4.1 
CTMS_2 79.4 1.5 
CTMS_3 /* 
 
   
CDMPS_1 33.2 0.8 
CDMPS_2 49.6 1.1 
CDMPS_3 /* 
 
   
CDPMS_1 34.4 0.2 
CDPMS_2 35.0 0.1 
CDPMS_3 /* 
 
   TPCS_1 44.2 0.2 
TPCS_2 61.4 1.1 
TPCS_3  /*   
* no determination possible due to technical issues 
Based on results gained in this section and in section 4.2.1.1, four differently modified 
GBs, namely FPTS_1, FPTS_2, CDPMS_2 and TPCS_2 were selected, while 
GB_UT served as a control. Hereby, a wide range of CAs as well as dispersive sur-
face energies was covered (Figure 4-12). Further investigations presented in this 
chapter will focus on these five carriers.  
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Figure 4-12 Overview of GB characteristics (+StD) sorted by ascending CAs (n=3) 
Even though measurements conducted at infinite dilution are generally reliable since 
they are characterised by major sensitivity, they only represent the highest proportion 
of γs
d present on the respective sample [166]. For that reason, iGC was also employed 
to generate distribution profiles to investigate the dispersive surface energy distribu-
tion across the whole carrier surface. Therefore, increasing volumes of same alkanes 
used to determine the γs
d were injected and adsorption isotherms were measured. As 
a result, surface energies at particular surface coverages (n/nm) are displayed (Figure 
4-13). Chemically modified GBs showed a steep negative slope at low coverages, 
while a widely constant energy was measured when coverage was increased. It 
needs to be noted that the extent of decrease differed significantly for the different 
modified GBs. GB_UT on the other hand presented a constant decrease of  γs
d. 
Each type of GB exhibited a heterogeneous distribution profile regardless of the modi-
fication indicated by varying dispersive surface energies at higher surface coverages. 
It can also be taken from Figure 4-13 that chemically modified GBs reached a con-
stant γs
d above a certain surface coverage. In contrast, the surface energy profile of 
GB_UT decreased across the whole range of surface coverages. 
Heterogeneity of distribution was least pronounced for GB_UT, where γs
d only varied 
from 36.0 mJ/m² to 42.5 mJ/m². A constant reduction of surface energy indicates a 
statistically even distribution of high and low energy sites [167]. Widely differing distri-
bution profiles were experienced for modified GBs. On TPCS_2, sites of high ener-
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gy (63.0 mJ/m²) were determined. A comparatively low γs
d of 37.8 mJ/m² was meas-
ured on other regions of the surface. These observations confirm the presence of ac-
tive sites on each type of carrier. But the silanisation process did not alter the whole 
carrier surface the same way. This is indicated by the increase of heterogeneity of 
surface energy distribution through chemical modification. In addition, differences in 
the extent of γs
d decrease indicate that the impact of silanisation is highly dependent 
of the respective agents. 
 
Figure 4-13 Dispersive surface energy profiles of GB_UT and silanised GBs 
4.2.1.3 Particle Size and Shape 
After silanisation, modified GBs were examined with respect to possible alteration in 
their size and shape compared to GB_UT. Those factors have been proven to impact 
the respirable fraction to a certain extent (section 2.3.3). As merely investigating the 
impact of a specific surface alteration was the overarching goal in this study, no signif-
icant change in other characteristics was defined as fundamental requirement for a 
suitable surface modification technique.   
It can be taken from Figure 4-14 (top) that chemical modification did not alter the PSD 
of GBs significantly. Furthermore, particle sphericity remained unaffected by the si-
lanisation process (Figure 4-14 (bottom)). These findings provide the basis for further 
experiments, as any changes observed in drug loading or aerodynamic performance 
could directly be correlated to the respective modification. 
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Figure 4-14 PSDs (+StD) with logarithmic scaling on the x-axis (top) and particle sphe-
ricities (bottom) of GB_UT and silanised GBs (n=3) 
4.2.1.4 Flow Properties 
Potential changes of flow properties induced by silanisation were also of interest. In-
vestigations included determination of BFE, which is defined as the energy required 
inducing a certain flow pattern in a defined and conditioned volume of powder.  
Incubation of GBs with silanes in a concentration of 0.05 M slightly reduced flowability 
as seen for CDPMS_2, FPTS_2 and TPCS_2 (Figure 4-15). FPTS_1 exhibited a sig-
nificant decrease in BFE (165.0 ± 7.0 mJ) compared to GB_UT (184.7 ± 11.0 mJ) 
substantiating the suggestion that solely a high silane concentration of 0.5 M was suf-
ficient to ensure saturation of the entire GB surface. In general, a low BFE is desirable 
Results and Discussion 
73 
 
as it indicates proper flowability. This ensures processability, e.g. precise dosing dur-
ing capsule filling.   
 
Figure 4-15 BFEs (+StD) of untreated and modified GBs (sorted descending) (n=10) 
4.2.2 Influence on True Surface Coverage 
Based on mathematical operations presented in section 3.3.4, blends consisting of 
untreated or modified GBs and API were prepared with different CSCs of 100 %, 
50 % and 25 %. In general, drug loading can be seen as an important factor for aero-
dynamic performance, as it was described to influence the amount of API delivered to 
the lungs [74]. This highlights the necessity to examine the TSC of the blends used 
for impaction analysis. Potentially varying drug loadings at a constant amount of API 
originally weighed in (CSC) were investigated in regard to the respective surface 
modifications.  
TSCs of BUD were found to be lower than the corresponding CSCs (Figure 4-16). 
This is true for GB_UT and also for modified GBs. Furthermore, the effective drug 
loading was highly dependent on the amount of API originally weighed in, whereby a 
CSC of 100 % led to the highest TSC in any case. Fewest overall amount of drug was 
attached to GB_UT at 47.6 ± 1.9 % TSC after blending and extended drug load was 
reached by TPCS_2 at 78.6 ± 2.2 % for 100 % CSC.  
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Figure 4-16 Resulting TSCs (+StD) for the different CSC of 100 %, 50 % and 25 % of 
BUD plotted against CA (top) and 𝛄𝐬
𝐝 (bottom); sorted ascending according to the re-
spective CAs or 𝛄𝐬
𝐝 ; the dotted line represents 𝛄𝐬
𝐝 of BUD (n=10)  
The decreased TSCs compared to the respective CSCs indicate that not the entire 
quantity of API was attached to the carrier during blending. This is supported by pic-
tures taken from the mixing vessel after blending (Figure 4-17). A substantial fraction 
of drug was located inside the mixing vessel whereby a thin layer covered its inner 
walls. This can be ascribed to processes taking place during blending. Here, particle- 
wall collisions and frictional forces occur. This triggers an opposite net charge of mix-
ing container wall and particles within the interactive mixture leading to a persisting 
attachment of the small API. The following paragraphs will examine the extent to 
which the API was attached to the different GBs in relation to surface modifications. 
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Figure 4-17 Mixing vessels after blending of GB_UT with BUD (left) or FF (right) 
Figure 4-16 (top) displays the correlation between CA and TSC. Here, GB_UT exhib-
ited the lowest drug loadings. By increasing surface hydrophobicity, which is ex-
pressed by an increase in CA, the amount of API located on the carrier was enhanced 
step-wise.  
Findings can conclusively be linked to physico-chemical properties of carrier and API. 
While BUD is a very hydrophobic model drug, free silanol groups convey extended 
hydrophilicity to the GB surface. Attractive forces between BUD and this GB type are 
presumably limited leading to a smaller proportion of API being attached to carrier 
surface during blending. Carrier hydrophobicity was subsequently increased through 
the incubation with different silanes, which is displayed by higher CAs. By that, attrac-
tive forces between carrier and BUD were enhanced to ultimately increase the TSC. 
These observations generally hold true for each TSC but are most explicit for a CSC 
of 100 %.   
Prima facie, no clear correlation between TSC and γs
d could be established (Figure 
4-16 (bottom)). If, however, the γs
d of BUD (48.5 mJ/m²) is taken into account, a spe-
cific pattern emerges. While a small difference in dispersive surface energy between 
API and carrier appeared to be unfavourable, a substantial difference was beneficial 
for an efficient drug loading as FPTS_2 and TPCS_2 showed highest TSCs. Those 
findings will be interpreted and put into context in the following.  
As far as FF is concerned, a TSC of 100 % could not be reached here either regard-
less of the carrier modification (Figure 4-18). 
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Figure 4-18 Resulting TSCs (+StD) for the different CSC of 100 %, 50 % and 25 % for FF 
plotted against CA (top) and 𝛄𝐬
𝐝 (bottom); sorted ascending according to the respective 
CAs or 𝛄𝐬
𝐝; the dashed line represents 𝛄𝐬
𝐝 of FF (n=10) 
The same applies to the other blends with 50 % or 25 % CSC where the effective 
drug load was always lower than the targeted one. Furthermore, silanisation showed 
a considerable impact as varying TSCs between 47.6 ± 2.0 % and 88.9 ± 1.7 % were 
obtained (for 100% CSC), whereby lowest amount of drug were located on GB_UT. 
The largest quantity of drug was attached to CDPMS_2.   
Here, no clear correlation between TSC and CA could be established (Figure 
4-18 (top)). It might be argued that, as far as only modified GBs are concerned, higher 
drug loadings were found for more hydrophilic material (low CA) and accordingly low-
er TSCs for GBs with the highest CAs. This is conclusive in terms of FF being more 
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hydrophilic than BUD. Following this reasoning, the presence of extended attractive 
forces between hydrophilic carriers and FF enhanced the drug loading, whereas ex-
tended hydrophobic properties impeded the attachment of FF. 
Figure 4-18 (bottom) takes the respective dispersive surface energies into account. 
Again, this did not lead to any distinct dependence to the drug loading. Nevertheless, 
a correlation could be established by implementing the γs
d of FF (34.0 mJ/m²). Inter-
estingly, a small difference between the γs
d was advantageous as blends containing 
CDPMS_2 exhibited the highest TSC which is contradictory to findings obtained 
for BUD. It needs to be noted that only the dispersive part of surface energy was tak-
en into account in this study. But the total surface energy also comprises the acid-
base component which described polar interactions. This could potentially put findings 
in a broader context. Nevertheless, Traini et al. investigated the role of surface energy 
on FPF and found the same inverse relationship between the two for the dispersive 
as well as the total surface energy [83]. This validates the present conclusions. 
4.2.3 Impaction Analysis 
The introduced modification technique has proven to be suitable to alter GB proper-
ties on a chemical level (section 4.2.1). As other material properties of the carrier re-
mained mostly unaffected, the impact of the alteration of chemical surface properties, 
could be directly correlated to aerodynamic performance determined by impaction 
analysis (NGI). The FPF provided a measure for the effectiveness, with which the API 
could reach the lungs. Additionally, FPD was determined to receive information of the 
total dose of particles with an aerodynamic diameter < 5 µm. 
In general, CSC substantially affected the respirable fraction and a CSC of 100 % 
always led to the highest FPF (Figure 4-19). This applies to all types of GBs and is 
true for both APIs. For BUD, FPFs between 11.2 ± 1.0 % and 19.5 ± 2.4 % were ob-
tained among the different carriers (for 100 % CSC). Best overall aerodynamic per-
formance was exhibited by blends containing GB_UT and lowest FPFs were identified 
for FPTS_2 (Figure 4-19 (top)). For FF, respirable fractions ranging from 
14.9 ± 1.9 % (CDPMS_2) to 26.6 ± 0.7 % (FPTS_2) were observed in impaction anal-
ysis (Figure 4-19 (bottom)). 
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Figure 4-19 FPFs (+StD) of blends containing different GBs and BUD (top) or FF (bot-
tom) for CSCs of 100 %, 50 % and 25 % (n=3) 
Relatively low FPFs were gained when using interactive mixtures containing GBs as 
carriers compared to those prepared with commonly used lactose [168,169]. The ob-
servation can be linked to fundamental differences between properties of lactose and 
GBs. It is well recognized that carrier size is an important parameter for aerodynamic 
performance of DPI formulations [74,76]. This was, inter alia, ascribed to higher frac-
tions of API persistently attached to larger carrier particles during inhalation, which 
were recovered from the preseparator [13]. Smaller carrier particles such as present 
in lactose would also lead to more frequent carrier-carrier collisions and an increased 
frictional contact area triggering drug detachment [23]. Although previous studies em-
ployed conventional carriers, considerations also hold true for GB as well. This is 
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substantiated by findings from Ooi et al., where blends containing polystyrene 
spheres in different sizes were utilised as carrier [59]. Again, more drug particles re-
mained on larger spheres resulting in diminished aerosol performance.  
Previous studies based the influence of drug loading on the FPF on a heterogeneous 
surface energy distribution on the carrier surface [170]. First and foremost, this leads 
to a preferable binding of drug particles to certain areas, characterised as highly en-
ergetic, on the carrier surface during blending. This was initially described by Her-
sey [171], while those areas were introduced as so-called active sites [172]. Second-
ly, active sites convey extended binding energies oftentimes forcing a persisting at-
tachment to the carrier during inhalation [173,174]. As a result, the following conclu-
sions can be drawn: At high drug loading, only a limited percentage of API is attached 
to those active sites where AFs are potentially higher than the energy imparted in the 
course of inhalation. Most of the drug will be present elsewhere (low energy sites). 
Consequently, sufficient drug detachment is observed during inhalation. In contrast, a 
substantial fraction of API will be located on high energy sites at low drug loading, 
leading to a decreased FPF compared to a high drug load (Figure 4-19). This is rep-
resentatively supported by SEM micrographs of blends containing GB_UT or 
CDPMS_2 and FF for the other interactive mixtures (Figure 4-20). At a high effective 
drug loading of 88.9 ± 1.7 % (CDPMS_2, 100 % CSC), the API appears to be fairly 
even distributed across the carrier surface. As the TSC decreases, preferential bind-
ing to certain areas becomes visible (50 % and 25 % CSC). Due to a low effective 
drug load of GB_UT, inhomogeneous distribution arises at the highest CSC of 100 %. 
It has been reported for conventional carriers like lactose that active sites are created 
during manufacturing or by surface-alteration of the particles [175]. In the present 
study, iGC measurements have already proven the presence of high energy spots on 
any type of GB (section 4.2.1.2), to which observed results can be linked in a coher-
ent way. 
It needs to be noted, however, that the aerodynamic performance can only be en-
hanced up to a certain point by increasing the drug loading [176]. It reaches a plat-
eau, where further addition of API does not increase respirable fraction. Instead, ag-
glomeration of drug particles and the formation of multilayers on the carrier surface 
occur to ultimately reduce the FPF and FPD [173].   
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Figure 4-20 SEM micrographs of blends containing FF and GB_UT (top) or CDPMS_2 
(bottom) at different CSCs 
Section 4.2.2 highlighted the surface modification governing TSC. Furthermore, it has 
been reported in the previous section that drug loading had a crucial impact on aero-
dynamic performance. Therefore, the introduction of a standardisation technique be-
comes mandatory in order to profoundly compare the different interactive mixtures 
regarding their FPFs. As a first step for this, obtained TSCs for CSCs of 100 %, 50 % 
and 25 % were plotted against their resulting FPFs, exemplary illustrated in Figure 
4-21 for the blends containing GB_UT and BUD. The second step comprised calculat-
ing the FPF for a fictive TSC set at 30 %. This drug load was chosen for comparative 
purposes since on the one hand each API-carrier combination reached this particular 
TSC despite notable differences observed in drug adhesion. On the other hand, the 
absence of larger drug agglomerates and no partial multi-layer formation could be 
presumed under these conditions. 
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Figure 4-21 Illustration for the mathematical determination of FPF exhibited by a blend 
with a defined TSC of 30 % exemplary for GB_UT and BUD 
By doing so, gained calculated FPFs were comparable and could directly be correlat-
ed to carrier surface characteristics. In the course of this, CA had a distinctive effect 
on the respirable fraction of BUD, while the highest FPF of 14.4 % was achieved by 
hydrophilic GB_UT (Figure 4-22). In addition, respirable fraction of BUD decreased 
with increasing CA of the carrier. This displayed a reverse trend compared to the rela-
tionship between CA and TSC.  
 
Figure 4-22 Resulting FPFs of blends containing BUD or FF and different GBs at a de-
fined TSC of 30 % plotted against their corresponding CAs; sorted in ascending order 
according to CA 
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Observations can be dedicated to API and carrier characteristics in a coherent way. 
During inhalation, adhesive forces present in interactive mixtures must be overcome 
to initiate drug detachment. These forces appear to be highly dependent on chemical 
properties. The potential for interaction between BUD and GB_UT was already de-
scribed as the lowest among the GBs (section 4.2.2). Although these limited interac-
tive forces led to a low TSC on the one hand, it facilitated drug detachment on the 
other. By introducing hydrophobicity to the carrier surface, FPF was significantly de-
creased to 5.6 % for BUD, while adhesive forces were increased accordingly. 
Figure 4-23 displays the correlation between γs
d and FPF, which becomes apparent 
upon implementing γs
d of the respective APIs (BUD: 48.5 mJ/m²; FF: 34.0 mJ/m²). For 
BUD, a negligible difference between carrier and API was desirable to ensure proper 
respirable fractions, while the opposite effect of was observed when γs
d  varied con-
siderably.  
 
Figure 4-23 Resulting FPFs of blends containing BUD or FF and different GBs plotted 
against their corresponding 𝛄𝐬
𝐝; sorted in ascending order according to 𝛄𝐬
𝐝; dotted and 
dashed lines represent 𝛄𝐬
𝐝 of BUD and FF, respectively 
Interestingly, this displayed the opposite trend compared to the effect of γs
d on drug 
loading. Although the impact on TSC and also on FPF could not entirely be explained 
by evaluating them separately, combining the findings provides a plausible conclu-
sion. For a hydrophobic API like BUD it might be assumed that similar dispersive sur-
face energies induce low adhesive forces consequently leading to a limited TSC, but 
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an enhanced FPF. In contrast, substantial differences in γs
d generate more potential 
for interaction affecting the TSC and FPF in a contradictory way.  
FF showed distinctively different behaviour in terms of respirable fractions (Figure 
4-22) exhibiting FPFs in the range of 8.7 % – 18.8 % for FPTS_1 or GB_UT, respec-
tively. As far as only blends containing modified GBs are taken into account, FPF was 
correlated to the CA in a positive manner. Here, reverse considerations compared to 
those for BUD are applied. It is hypothesised, that the detachment of rather hydro-
philic FF was facilitated when carrier hydrophobicity was increased (as indicated by 
higher CAs) leading to this opposite trend. 
Not only CAs but also γs
d triggered differing respirable fractions (Figure 4-23). A slight 
difference between carrier and FF proved to adversely influence the FPF. This might 
also be explained in accordance with findings of the TSCs. For rather hydrophilic FF, 
approximately equal γs
d of carrier and API potentially express enhanced adhesive 
forces, indicated by maximum drug load but minimum FPF due to impaired detach-
ment.  
In addition to BUD and FF, blends containing GBs and TB sd were examined (data 
not shown). Results demonstrated that no correlation between surface characteristics 
and neither drug loading nor aerodynamic behaviour could be established. It needs to 
be noted here that despite the incubation with partially hydrophobic silanes, carrier 
surfaces remained rather hydrophilic, as CAs below 90° equal hydrophilic materials 
by definition. It is presumed that distinctive differences in drug loading and aerody-
namic performance of polar APIs can solely be observed when implementing very 
hydrophobic materials. This would enable the investigation of an even broader range 
of chemical properties. As another consequence, the characteristics and behaviour of 
blends containing hydrophobic BUD could completely be linked to carrier properties. 
As hydrophilicity of the API was increased by implementing FF, fewer correlations 
could be established compared to BUD. 
Up to this point, focus has been put on the efficiency with which the drug was deliv-
ered to the lower airways expressed as the percentage charge of particles with an 
aerodynamic diameter < 5 µm (FPF). This is generally considered adequate if a single 
preparation with a constant API content is tested on different inhalation devices, for 
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example. In the present study, blends with varying drug loading were examined, since 
the total amount of drug delivered to the lungs expressed as FPD needs to be taken 
into account as well. 
As expected, a CSC of 100 % led to the highest amount of fine BUD particles regard-
less of the modification (Figure 4-24). Blends containing CDPMS_2, FPTS_2 or 
GB_UT resulted in comparable FPDs (100 % CSC). Highest and lowest FPDs were 
reached for TPCS_2 (325 ± 25 µg) and FPTS_1 (164 ± 43 µg), respectively. 
 
Figure 4-24 FPDs (+StD) of blends containing different GBs and BUD at CSCs of 100 %, 
50 % and 25 % (n=3) 
Although blends containing TPCS_2 did not show optimal efficiency, i.e. they did not 
distribute the most API to the target site percentage-wise, they were able to deliver 
the highest total amount of drug overall due to the maximum drug loading displaying a 
greater balance of adhesive forces between carrier and API. This identifies TPCS_2, 
or more precisely the chemical properties of TPCS_2 as being optimal for a carrier-
based formulation of BUD.  
Consequently, the carrier used to form an interactive mixture with BUD should exhibit 
the same or at least very similar properties compared to TPCS_2 in terms of hydro-
phobicity and dispersive surface energy. This ensures that the majority of API is at-
tached to the carrier during blending while a sufficiently low detachment energy is re-
quired for drug dispersion. 
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Figure 4-25 FPDs (+StD) of blends containing different GBs and FF at CSCs of 100 %, 
50 % and 25 % (n=3) 
Figure 4-25 illustrates the resulting FPDs obtained from blends with different GBs 
and FF. Here, no significant difference was observed between any of the GBs. This 
implies for the use of rather hydrophilic APIs that chemical surface properties in the 
examined range do not impact the overall performance of the interactive mixture. In-
stead, the positive impact of adhesive forces on drug loading and its negative effect 
on respirable fraction appeared to outbalance each other.  
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4.3 Alteration of Carrier Surface Topography 
In this chapter, different techniques to modify topographical parameters of GBs are 
presented. This approach aimed at a targeted introduction of roughness to the sur-
face on micro- and nano-scale as well as a combination of both. The effect of these 
modifications is subsequently correlated to TSC and aerodynamic performance. Ini-
tially, untreated and physically modified GBs were blended with BUD or FF, both in 
spray-dried quality, at different CSCs of 100 %, 50 % and 25 %. Again, only blends 
with a sufficient content uniformity (rStD < 5 %) were employed. 
4.3.1 Characterisation of Glass Beads 
The effect of modification techniques on the carrier surface described in sec-
tion 3.3.2.2 was investigated using two different methods, namely SEM and AFM. 
Figure 4-26 shows representative SEM micrographs of untreated and modified GBs at 
100-, 500- and 2500-fold magnifications. GB_UT presented an overall smooth surface 
with occasional irregularities (clefts and ridges) that become visible at the highest 
magnification. The incubation of GBs with HF led to micro-scale indentations on the 
surface. It can be taken from micrographs of HF10min, HF+TC4h and HF+TC8h that 
introduced cavities were of various shapes. While some looked crescent-like, others 
appeared nearly hemispherical. Additionally, they significantly differed in depth and 
diameter. Grinding with tungsten carbide caused numerous nano-scale irregularities, 
e.g. seen for TC4h. At the same time, the number of ridges present on GB_UT was 
reduced to a large extent. It also becomes obvious that an extended milling time of 
eight hours intensified the effect as the surface of TC8h was abraded to a greater ex-
tent area-wise compared to TC4h. GBs which have been subjected to both modifica-
tion steps showed both micro-scale, HF induced, and nano-scale, TC milling induced, 
roughness (HF+TC4h and HF+TC8h).  
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Figure 4-26 SEM micrographs of GB_UT and surface modified GBs at 100-fold, 500-fold 
and 2500-fold magnification (top, middle and bottom, respectively) 
AFM enabled a more precise visualisation of GB surfaces and also allowed the quan-
tification of micro- or nano-scale roughness by mapping the surface in tapping mode 
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to consequently calculate the corresponding Rrms values. As already observed by 
SEM, GB_UT were characterised by a fairly even surface with just a few discontinui-
ties (Figure 4-27).  
 
Figure 4-27 Representative micrographs of GB surfaces visualised via AFM 
This is also supported by a low Rrms value of 21.2 ± 7.4 nm (Figure 4-28). Milling with 
TC for four hours increased the surface roughness to 46.0 ± 8.3 nm (TC4h), while an 
eight hour treatment enhanced the Rrms value further to 64.2 ± 9.3 nm (TC8h). It can 
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be derived from Figure 4-27 that the density of surface irregularities was increased 
compared to TC4h during the extended milling. Taking the micrographs from Figure 
4-27 into account, HF10min exhibited a drastically increased Rrms value of 
697 ± 488 nm due to the respective frequency and depth of extended asperities lo-
cated on the scan area.  
It needs to be emphasised that the Rrms does not reflect the frequency of occurrence 
of surface roughness (equation 12). Instead, it provides information about the level of 
asperities. If AFM micrographs are additionally taken into account, the extended mill-
ing time protocol did only increase the occurrence of surface roughness area-wise, 
but also the depth of asperities. 
Due to the experimental setup, it was not possible to quantify roughness of HF+TC4h 
and HF+TC8h across the whole surface as sensitivity of the cantilever could solely be 
adjusted to micron or submicron irregularities. This limitation of AFM is widely accept-
ed and has been acknowledged in literature [82]. Therefore it was decided to focus 
investigations on regions on the carrier surface where no evident alteration through 
HF had taken place. These findings correspond well to the Rrms values of TC4h and 
TC8h (Figure 4-28). 
 
Figure 4-28 Rrms (+StD) values of GB_UT and modified GBs representing the extent of 
nano scale roughness. Results of HF10min have been excluded to increase clari-
ty (n=75) 
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4.3.1.1 Particle Size and Shape 
After modification, GBs were checked for particle size and shape to ensure compara-
bility of these properties. In addition, a different batch of GB_UT was utilised for this 
study making a re-measurement of the starting material necessary. Considering the 
PSDs, alteration of surface topography resulted only in a slight decrease in particle 
diameter regardless of the modification technique (Figure 4-29 (top)). Particle shape 
was altered to a small extent as well, as sphericity was increased during HF treatment 
and/or milling with TC (Figure 4-29 (bottom)). 
 
 
Figure 4-29 PSDs (+StD) with logarithmic scaling on the x-axis (top) and particle sphe-
ricities (bottom) of GB_UT and surface-modified GBs (n=3) 
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Marginal changes in PSD can be linked to the processes occurring during the actual 
modifications. HF is known to etch glass and therefore slight decreases in GB diame-
ter would be expected. Furthermore, ball milling of GBs with TC does not only induce 
roughness but also abrades the surface to some extent. Besides, both techniques 
potentially erase irregularities present on the carrier particles leading to an overall 
increased sphericity. It needs to be acknowledged that neither modification signifi-
cantly influenced the overall shape or particle size when comparing x50 values or 
mean sphericities. As mentioned earlier, this was defined as fundamental requirement 
to a suitable surface modification technique.   
4.3.1.2 Powder Rheometry 
Surface alteration influenced flowability as seen in BFE measurements (Figure 4-30). 
Here, BFEs ranging from 123.3 mJ up to 208.7 mJ were obtained. Milling with TC for 
4 hours led to a substantial decrease in BFE compared to GB_UT, whereas an 8 hour 
treatment time increased it again. The highest BFE was observed for HF10min. 
 
Figure 4-30 BFEs (+StD) of untreated and modified GBs (n=7) 
In general, it is assumed that a low BFE, with few exceptions, indicates enhanced 
flowability [177]. Therefore, an increase in BFE caused by roughness on micro-
scale (HF10min) illustrates deteriorated flow properties. Although surface cavities are 
not large enough to induce intensive mechanical interlocking, they potentially lead to 
extended interaction between the particles. Consequently, higher forces need to be 
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applied to establish the particular flow pattern in this setup. On the contrary, a signifi-
cantly lower energy needed to move the blade through the samples during the down-
ward traverse was experienced for GBs milled with TC (TC4h, TC8h). This can be 
attributed to the reduction of ridges present on the surface of GB_UT through the mill-
ing process. However, the extended milling time led to rougher particles diminishing 
flowability again.  
Another applied technique in this context was the wall friction test, as it allowed the 
examination of interactions between carrier and inhaler wall material. Figure 4-31 
gives measured WFAs in the range of 10.0° to 12.7° for the different GBs indicating a 
slight increase for GBs with nano-scale roughness on the surface (TC4h, TC8h). Ad-
ditionally, incubation with HF enhanced the WFA further.  
 
Figure 4-31 WFAs (+StD) of different GBs on wall material of the Modular Inhaler (n=7) 
In summary, the introduction of surface roughness, regardless of its scale, had an 
enhancing effect on frictional forces between carrier and wall material. This corre-
sponds well previous studies where the WFA could be correlated to surface rough-
ness in a positive manner [178]. 
4.3.2 Influence on True Surface Coverage 
This study employed two APIs, namely BUD and FF in spray-dried quality. TSCs were 
evaluated to examine the impact of surface modifications on effective drug loading at 
different CSCs. In general, an effective surface coverage of 100 % could not be 
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reached (Figure 4-32). Moreover, the TSC was always lower than the correspond-
ing CSC. This is true for both APIs and all types of GBs. It also becomes clear that a 
nearly linear relationship between theoretical and effective drug loading was obtained. 
This illustrates a distinct correlation between the API quantity originally weighed in 
and the true fraction attached to the total GB surface. 
 
 
Figure 4-32 Correlation between CSCs and the corresponding TSCs (+StD) for interac-
tive mixtures containing GBs and FF (top) and BUD (bottom) (n=10) 
Figure 4-32 (top) shows results for FF, where highest overall resulting TSCs were 
exhibited by the blend containing GB_UT at 57.5 ± 1.3 %, 30.5 ± 0.9 % and 
14.9 ± 1.7 % for 100 %, 50 % and 25 % CSC, respectively. TC4h displayed a sub-
stantial decrease in terms of effective drug loading while an extension of milling time 
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to 8 hours led to further reduction of TSC to 38.1 ± 1.5 %, 19.0 ± 0.7% and 
11.1 ± 0.4 % for 100 %, 50 % and 25 % CSC, respectively. Blends containing BUD 
exhibited contrary results (Figure 4-32 (bottom)). Highest TSCs were observed when 
using GBs which had been subjected to TC milling. Again, a milling time of 8 hours 
showed the more distinctive effect with TSCs of 74.3 ± 0.8 %, 40.5 ± 1.3 % and 
20.4 ± 0.2 %. The application of a milling step increased the drug loading in general 
which becomes evident when comparing results for HF10min, HF+TC4h and 
HF+TC8h. An extended milling protocol amplified this effect as well. For the most 
part, the overall tendencies described above were found for all three different cover-
age rates but are most prominent for the highest CSC of 100 %. 
As already pointed out, results presented lower TSC compared to the corresponding 
CSC in any case. This was again due a substantial proportion of API being adhered 
to the inner walls of the mixing vessel after blending (see section 4.2.2). The degree 
of drug recovery from the mixing vessel was determined to be dependent on the re-
spective modification. For FF, the highest drug loading was reached on GB_UT. This 
was due to the physico-chemical properties of drug and carrier. For the latter, free 
silanol groups bring hydrophilicity to the surface. FF is also rather hydrophilic com-
pared to BUD. In consequence, interaction between carrier and FF will be conveyed 
by hydrogen bonds to a certain extent leading to comparably high AFs for GB_UT and 
the API. Grinding with TC introduced submicron surface roughness as confirmed by 
AFM. Thus, a reduction of contact area between carrier and API is expected (Figure 
4-33). Here, less contact area ultimately led to weaker binding of FF to the GB sur-
face causing to the lowest TSCs for TC4h and TC8h.  
 
Figure 4-33 Schematic illustration of a plain untreated GB surface (left) and a surface 
subjected to TC milling (right) occupied with spray-dried API particles 
In theory, BUD should bind to the hydrophilic GB surface to a limited extent on ac-
count of a minor potential for interaction (mainly van-der-Waals forces) relative to FF. 
This was proven by lower TSCs for blends containing GB_UT and BUD compared to 
those with GB_UT and FF and additionally by comparing blends with HF10min and 
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BUD to those with HF10min and FF. In the case of BUD, roughness on nano-scale 
led to an enhanced effective drug loading. It is suggested that the hydrophobic drug 
particles are more likely to bind to the hydrophilic GB surface, if contact area is re-
duced. But this only holds true in the presence of repulsive forces between carrier and 
API. Although the net charge of components in interactive mixtures has not been 
tested with the present setup, a study performed by Elajnaf et al. supports the theo-
ry [179]. That study investigated, inter alia, the effect of blending on the electrostatic 
charge of carrier and API. Here, interactive blends of salbutamol sulphate and carrier 
lactose were employed showing that both components got charged negatively during 
tumble blending in a stainless steel mixing container. This was ascribed to electron 
transfer from the container material inducing negative net charge of carrier and API 
particles which ultimately triggered repulsive forces between the two. Furthermore, 
electron-acceptor (γ+) and electron-donor (γ-) parameters were examined for various 
container materials by contact angle measurements with different liquids [180]. These 
materials included not only different metals, but also glass. It was discovered that γ-/γ+ 
was four times higher for stainless steel than for glass, indicating a high probability for 
electron transfer from the mixing vessel to GBs.  Applying this theory to the present 
study, both carrier and API should get charged negatively during blending. This would 
indicate the existence of repulsive forces conclusively explaining highest TSCs for 
TC8h. 
It can be taken from Figure 4-32 that BUD exhibited higher overall TSCs compared to 
FF which might seem incomprehensible as far as chemical properties of the APIs are 
considered. Nevertheless, observations made during the optimisation of blending 
conditions might provide a plausible rationale. Preparing homogeneous blends con-
taining BUD required solely a blending time of 30 min at 20 rpm. In contrast, a blend-
ing protocol of 35 min at 20 rpm followed by 5 min at 30 rpm had to be applied to en-
sure sufficient drug loading and adequate homogeneity when using FF. This implies 
that the ratio of cohesive to adhesive forces is higher for FF causing the formation of 
agglomerates which are not attached to the carrier surface. 
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4.3.3 Impaction Analysis 
Figure 4-34 (top) displays respirable fractions of interactive mixtures containing 
GB_UT and modified GBs blended with FF. For each type of GB, three different 
CSCs were investigated. In general, a distinctive trend concerning the effect of drug 
loading on aerodynamic performance analogous to that in section 4.2.3 was identi-
fied. The respirable fraction was improved when increasing the CSC. This is true for 
each blend under investigation and applies to both APIs.  
 
 
Figure 4-34 FPFs (+StD) of blends containing different GBs and FF (top) or BUD (bot-
tom) for CSCs of 100 %, 50 % and 25 % (n=3) 
When evaluating the impact of surface modifications, a significant decrease in FPF 
through the introduction of micron-sized roughness becomes apparent. For FF, res-
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pirable fraction decreased from 25.6 ± 0.9 % for GB_UT to 15.1 ± 0.5 % for 
HF10min (100 % CSC). Through the addition of a milling step with TC, respirable 
fractions could be increased again almost to the level of GB_UT as seen for 
HF+TC8h. The enhancing effect on respirable fraction is further displayed by major 
FPFs exhibited by TC4h (26.1 ± 0.8 %) and TC8h (28.2 ± 0.2 %). Trends described in 
this section also hold true for BUD. However, absolute values of FPFs differed to a 
substantial extent from those obtained when using FF. Respirable fractions of BUD 
were experienced to be lower in any case (Figure 4-34 (bottom)).   
Again, the FPF was normalized to a fictive TSC of 30 % for each type of GB to direct-
ly compare the different blends as described in section 4.2.3. When evaluating the 
resulting FPFs of FF and BUD, it becomes clear that trends shown above are still ex-
istent (Figure 4-35). However, results can now be compared in a direct way regard-
less of differing TSCs.  
 
Figure 4-35 Resulting FPFs at 30 % TSC for untreated and modified GBs blended with 
FF (black bars) or BUD (grey bars) 
A significant decrease in respirable fraction was observed in the presence of deep 
cavities (µm range) for both APIs and SEM pictures provide a conclusive explanation 
for this. After blending, API particles had accumulated in those discontinuities (Figure 
4-36 (left)). This observation has been ascribed to an enhanced potential for adhesive 
forces in those regions [181]. In addition, API particles located in those active sites 
potentially find shelter from the airstream during inhalation which causes a persisting 
attachment onto the carrier surface. In the course of a recent revision of the active 
Results and Discussion 
 
98 
 
sites theory, it was proposed to define the activity of surface areas by their ability to 
shelter API particles from removal forces during inhalation directly linking drug disper-
sion to site activity [182]. In case of the Cyclohaler, those removal forces are mainly 
based on drag and lift process, while inertial impaction only plays a minor role for this 
device. Moreover, it was confirmed by examination of GBs taken from the presepara-
tor after inhalation routine. Figure 4-36 (right) shows indentations remaining occupied 
with a certain amount of drug. Even though a high flow rate of 100 L/min was applied, 
the kinetic energy of the air stream was evidently not high enough to detach the API 
causing a drastic decrease in respirable fraction. The same trend was existent when 
comparing FPFs of blends containing HF+TC4h or HF+TC8h to those containing TC4 
or TC8h, respectively.  
 
Figure 4-36 SEM micrographs of the interactive mixture containing HF10min and BUD 
at 50 % CSC before (left) and after inhalation (right) 
Consistent observations were made by Littringer et al., where mannitol carrier parti-
cles with large indentations of up to 50 µm in diameter were obtained through spray 
drying by adjusting process parameters [57]. They also experienced an accumulation 
of drug particles in those cavities leading to a lowered respirable fraction. In contrast, 
Dickhoff et al. found a beneficial effect of the presence of cavities on aerodynamic 
performance as they potentially protect drug particles from press-on forces created 
during the blending process [183]. It was acknowledged, however, that this potentially 
favourable effect might solely be relevant for inhalation devices where drug detach-
ment is triggered by inertial forces, e.g. Novolizer or Turbuhaler [84]. When using the 
Cyclohaler, where the dispersion principle is based on drag and lift forces, this is not 
expected as entrapped drug particles remain largely unaffected by those forces [181]. 
Hence, presented results for the impact of micron-scale roughness are primarily ap-
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plicable to inhalation devices that induce drug redispersion by mechanisms similar to 
the Cyclohaler, e.g. the Diskus.  
The presence of nano-scale roughness induced an increase in FPF, which is true for 
FF as well as BUD (Figure 4-35). Presumably, these submicron irregularities reduced 
the contact area between carrier and API and consequently diminished the potential 
for interaction between the two. This led to lower adhesive forces ultimately facilitating 
drug detachment to enhance the FPF. Again, the extended milling time showed an 
even more pronounced effect as superior FPFs were achieved when using TC8h. The 
obtained results are in good agreement with earlier findings by Kawashima et al., 
where a decrease in aerodynamic performance was determined for lactose particles 
with a smoothened surface [184]. This was ascribed to an increase in contact area 
leading to stronger van-der-Waals attractive forces. Despite obvious differences in 
chemical characteristics of FF and BUD, the same trends were observed as far as 
respirable fractions are concerned. A recent study carried out within the DFG priority 
program “PiKo” examined the effect of sub-micron surface roughness which was in-
troduced inter alia by plasma etching using salbutamol sulphate as API [81]. Obtained 
results showed a positive correlation between roughness and FPF. These findings 
imply that a decrease in contact area created through nano-scale roughness pro-
motes drug detachment regardless of chemical properties of the API.  
 
Figure 4-37 FPFs (+StD) for untreated and modified GBs blended with FF micro (black 
bars) or BUD micro (grey bars) (n=3) 
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Additionally, trials were carried out utilising the APIs in micronised quality. In the 
course of this, blends were prepared with an API to carrier ratio of 1:100 (m/m) as the 
irregular shape of the particles did not allow calculations concerning surface coverag-
es. A drug content of 1 % can also be considered as a common concentration in 
blends for inhalation. FF micro exhibited respirable fraction in the range 
of 15.1 ± 1.2 % to 25.4 ± 3.0 %. For its hydrophobic counterpart (BUD), FPFs be-
tween 11.4 ± 1.7 % and 18.7 ± 0.5 % were obtained (Figure 4-37). 
Here, GB treatment with HF again diminished the FPF whereas the introduction of 
nano-scale roughness facilitated drug detachment. This is true for both APIs. It also 
becomes apparent that the impact of micro-scale roughness was less pronounced for 
micronised drugs compared to the spray-dried quality. This implies a limited capacity 
of the indentations to withhold those drug particles during inhalation. Interestingly, 
higher overall FPFs were obtained for spray-dried compared to micronised APIs de-
spite lower mean particle sizes of the latter (Figure 4-38). These results may be linked 
to an improved aerodynamic behaviour of spray-dried particles due to, e.g. tailored 
spherical shape and lower density. 
 
Figure 4-38 PSDs with logarithmic scaling on the x-axis of BUD and FF in micronised 
and spray-dried quality 
To conclude, the presence of nano-scale roughness was favourable for an efficient 
drug detachment, while larger indentations hindered drug detachment subsequently 
reducing the aerodynamic performance. As shown in the present chapter, this is gen-
Results and Discussion 
101 
 
erally valid despite extensively varying morphological and chemical properties of the 
drug particles.  
However, as the blends differed in TSC, the amount of active delivered to the lungs 
expressed as FPD also has to be taken into account. This is because not only the 
fraction of API but also the total dose is of interest for pulmonary drug delivery. To do 
so, results gained for spray-dried APIs were evaluated again. 
 
 
Figure 4-39 FPDs (+StD) of blends containing different GBs and FF (top) or BUD (bot-
tom) for different CSCs of 100 %, 50 % and 25 % (n=3) 
As seen in Figure 4-39 (top) which displays FPDs of blends containing FF, some 
trends described earlier for the FPF are still existent but less pronounced. Albeit a 
decrease in respirable dose for HF10min (163.9 ± 3.7 µg for 100 % CSC) compared 
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to GB_UT (199.8 ± 5.2 µg for 100 % CSC), HF+TC8h, TC4h and TC8h presented 
comparable FPDs. Highest doses were found for HF+TC4h. As far as BUD is con-
cerned, distinctive tendencies regarding the effect of surface modification on the FPD 
were observed (Figure 4-39 (bottom)). Corresponding to FPFs, the amount of fine 
particles was decreased through HF treatment to 67.36 ± 6.5 µg (100 % CSC) while 
milling with TC led to an almost two-fold increase up to 423.1 ± 18.0 µg compared 
to 220.1 ± 40.0 µg for GB_UT.  
The FPD represents the total dose of API theoretically delivered to the lower airways 
and therefore can be seen as the result of the interplay between FPF and TSC. For 
FF, TC milling led to a substantial decrease in TSC (section 4.2.2) while respirable 
fraction was enhanced by that modification resulting in only medium FPDs. Lower 
respirable doses due to small FPFs were observed when applying HF treatment while 
it had a negligible effect on TSC. This is also true for BUD. Here, however, introduc-
tion of nano-scale roughness significantly increased the TSC. This modification had a 
positive effect on the FPF leading to drastically increased FPDs for TC4h and TC8h 
as well.  
4.3.4 Adhesion Forces 
The AF between two particles is equivalent in magnitude to the force which is re-
quired for their detachment or separation. Different measuring setups have been in-
troduced in the past years to investigate those forces including centrifugation, vibra-
tion and impact separation [185,186]. But these techniques only allow indirect deter-
mination of AFs as they measure the amount of particles which get detached under 
certain conditions. AFM, however, monitors the detachment of a single particle from 
another one providing precise measures of AFs. These investigations helped to fur-
ther enlighten the relationship between interparticle interactions and drug detachment. 
It can be taken from Figure 4-40 that HF treatment did not alter AFs between carrier 
and API, e.g. seen for GB_UT at 111.3 ± 30.5 nN and HF10min at 114.7 ± 38.9 nN. 
Milling with TC for 4 hours significantly decreased AFs (HF+TC4h and TC4h). The 
extended milling protocol led to further decrease illustrated for TC8h (26.18 ± 9.7 nN).  
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Figure 4-40 Adhesion forces (+StD) between GB_UT or modified GBs and BUD sd 
(n=75) 
Interestingly, the effect of HF treatment was negligible in any case. It can be conclud-
ed that no enhanced interactive forces prevail in the cavities in contrast to assump-
tions by de Boer et al. [181]. Therefore, those forces were not accountable for drug 
entrapment on the carrier surface in this setup. Instead, the present findings empha-
sise that the diminished respirable fractions were dependent on the ability of larger 
indentions to physically shelter the drug particles located inside from the airstream. 
However, the assumption of TC treatment leading to diminished contact area between 
carrier and API could be verified. Reduced adhesive forces can conclusively be relat-
ed to an enhanced aerodynamic performance of the respective blends. 
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4.4 The Importance of Inhaler Geometry 
Up to this point, focus has been put on the DPI formulation to explain aerodynamic 
performance by carrier surface characteristics. In this chapter, the role of the inhala-
tion device will be examined. The overall aim was the identification of inhaler parts 
with a significant impact on dispersion, deagglomeration and consequently on drug 
delivery efficiency. This was implemented with DoE approaches utilising the Modular 
Inhaler system (section 3.1.6.2). Different dimensioning of inhaler parts were defined 
as the respective factors within the experimental design. FPF, device retention (DR) 
and specific device resistance (SDR) were set as responses to be investigated. For 
comprehensive examination, two APIs, namely BUD micro and IB micro, were used 
each to form interactive mixtures with GB_UT. 
GBs are merely intended as a model carrier system. Beyond that, they exhibit widely 
different material characteristics compared to conventional carriers (Table 4-4). Thus, 
the present study should also point out differences and similarities in the aerodynamic 
behaviour of blends containing either GBs or lactose. In order to do so, obtained re-
sults were directly compared to those from Friebel [87], hereafter referred to as the 
earlier study. In that, different inhaler combinations have been examined using α-
lactose monohydrate as carrier.  
Blends were prepared according to [87] with a fixed drug content of 1.0 %. This ena-
bled a comparison of results using BUD micro and IB micro but replacing lactose by 
GB. Nevertheless, the setup of the study had to be adjusted due to GB properties as 
discussed in the following. 
Table 4-4 Characteristic properties of GBs in comparison to commonly used lactoses 
for inhalation [187–189] 
Property Lactohale® 100 Lactohale® 200 SiLibeads® Type S 
Particle size, µm 120 – 145 (x50) 50 – 100 (x50) 400 – 600 (size range) 
    
Poured density, g/L 690 650 2500 
Tapped density, g/L 840 950 2500 
    
Particle shape Irregular Irregular Spherical 
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4.4.1 Design of Experiments 
In the present experimental designs, a fractional factorial design (section 3.2.1) was 
applied to determine the practical relevance of device components for aerodynamic 
behaviour of the interactive mixture. For the upper part of the inhaler, different cross 
sectional areas (CSAs) of the mouthpiece were employed. Impact of the dimensioning 
of grid, i.e. stanchions width and free grid area, was of interest as well. Finally, di-
mensioning of the bottom part was investigated, where CSA of the air inlet and height 
of the deagglomeration chamber were varied (Table 4-5). Device retention was de-
fined as the combined fractions of API remaining in the device and the capsules after 
inhalation. The influence of the dimensioning on respirable fraction and DR of BUD 
and IB were systematically examined within these DoEs. In addition, the SDR was 
determined for each inhaler part combination to get information about the air flow ve-
locity within the device. Firstly, results were visually displayed in so-called contour 
plots to provide an overview of the range of the different responses. Secondly, the 
extent to which each significant factor affected the different responses was shown in 
coefficient plots. 
Table 4-5 Dimensioning of the upper part, grid and bottom part of the inhaler in sizes 
small (S), medium (M) and large (L)  
Dimensioning S M L 
Mouthpiece, CSA, mm² 7.06 21.30 35.54 
    
Grid, Free grid area, mm² 20.71 35.76 50.80 
Grid, Stanchions width, mm 7.06 21.30 35.54 
    
Air inlet, CSA, mm² 11.82 17.70 23.57 
Deagglomeration chamber, 
Height, mm 
7.00 8.00 9.00 
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4.4.2 Influence on Aerodynamic Performance 
Figure 4-41 visualises the effect of the different inhaler parts on the FPF of BUD, 
whereby values in the range of 14.1 ± 1.3 % to 31.4 ± 2.1 % were obtained. The di-
mensioning of all three components showed a significant effect on the FPF.  
 
Figure 4-41 4D Contour plot of the FPF for BUD as a response of the factors mouth-
piece CSA on the x-axis and grid (represented by the free grid area) on the y-axis. Re-
sults are given for the three different bottom parts represented by deagglomeration 
chamber height of 7, 8 and 9 mm; DA=Deagglomeration chamber 
 
Figure 4-42 Illustration of the significant effects of different inhaler parts on the FPF for 
BUD (coefficients scaled and centred). Gained values display the change in FPF, if the 
respective factor is changed by one level; MP=Mouthpiece, GR=Grid, 
DA=Deagglomeration chamber 
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Increasing the dimensioning of each inhaler part was unfavourable for the aerody-
namic performance. Accordingly, highest FPF was exhibited by the device composed 
of a small upper and bottom part as well as a small grid (Modular_S), while lowest 
FPF was experienced for overall large dimensioning (Modular_L). Additionally, a posi-
tive quadratic correlation of the grid became apparent (Figure 4-42).  
 
Figure 4-43 Contour plot of the FPF for IB as a response of the factors mouthpiece on 
the x-axis and grid (represented by the free grid area) on the y-axis 
 
Figure 4-44 Illustration of the significant effects of different inhaler parts on the FPF for 
IB (coefficients scaled and centred). Gained values display the change in FPF, if the 
respective factor is changed by one level; MP=Mouthpiece, GR=Grid, 
DA=Deagglomeration chamber 
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Dispersion behaviour of blends containing IB was governed by the dimensioning of 
MP and grid leading to FPFs between 14.7 ± 0.3 % and 35.2 ± 1.7 % (Figure 4-43). 
Again, increasing the dimensioning of the respective inhaler parts influenced the res-
pirable fraction in a negative way. In addition, a quadratic correlation (positive) to the 
mouthpiece occurred (Figure 4-44).  
The negative effect of an increased CSA of the mouthpiece can be ascribed to its im-
pact on the air stream velocity. In the present setup, a fixed flow rate of 60 L/min was 
applied to ensure sufficient entrainment of high density GB particles. At a constant 
flow, resistance of the inhalation device gets reduced when increasing the mouth-
piece diameter. This leads to a decelerated air stream. This can be derived from 
equation 17 which is applied to approximately determine the velocity (𝑉) within a spe-
cific inhaler part as a function of flow rate (𝑄). It is also supported by Computational 
Fluid Dynamic analysis presented by Coates et al., where a significantly lower exit 
velocity was determined for an increase in MP diameter of the inhalation device [190]. 
Consequently, less kinetic energy is transferred to the interactive mixture which low-
ers the effectiveness of drug redispersion. As a result, aerodynamic performance is 
reduced independently of API. 
𝑽𝒊𝒏𝒉𝒂𝒍𝒆𝒓 𝒑𝒂𝒓𝒕 =
𝑸∗𝟏𝟎𝟎𝟎
𝑪𝑺𝑨𝒊𝒏𝒉𝒂𝒍𝒆𝒓 𝒑𝒂𝒓𝒕∗𝟔𝟎
  equation 17 
In the earlier study, an opposite effect was documented. A large mouthpiece was fa-
vourable for an enhanced aerodynamic performance. This might seem contradictory 
at first sight, but is entirely coherent when experimental conditions are considered. 
The present study featured a consistent flow rate leading to varying pressure drops 
and thus different air stream velocities in the device for the different combinations of 
inhaler parts. The earlier study implemented the opposite approach, setting a con-
stant pressure drop of 4 kPa, defined by the Ph. Eur. as standard conditions. This 
resulted in varying flow rates and thus a constant air stream velocity [106]. It had 
been possible to apply this setup there due to the fundamental differences in carrier 
characteristics. Density and particle size were both much lower for lactose compared 
to GBs. By increasing the mouthpiece diameter, inhaler resistance was lowered. As a 
consequence, a higher flow rate was needed to maintain the 4 kPa pressure drop 
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which raised the kinetic energy of the airstream and the level of turbulence. This trig-
gered superior drug detachment. 
A small grid was needed to achieve higher respirable fractions for both APIs. It is as-
sumed that a smaller free grid space decelerates emptying of the capsule chamber. 
By that, the kinetic energy of the airstream was applied to the interactive mixture for 
the whole duration of the inhalation manoeuvre. This enhanced deagglomeration of 
interactive mixtures to ultimately increase the respirable fraction. This corresponds to 
findings from the earlier study and indicates that a slow and controlled discharge of 
the deagglomeration chamber is desirable regardless of carrier properties.  
For the hydrophobic BUD, the bottom part (air inlet and deagglomeration chamber) 
significant influenced respirable fraction. Tightening the air inlet and lowering the de-
agglomeration chamber enhanced the aerodynamic performance. On the one hand, 
this is also due to an increased air stream velocity at constant flow rate through a re-
duction of CSA of the air inlet. On the other hand, a smaller deagglomeration cham-
ber decreased the distance particles had to be lifted to leave the inhaler. The latter 
factor is certainly negligible for conventional carriers with a relatively low specific 
weight, but is relevant for high density GBs. Interestingly, the choice of the bottom 
part did not affect the respirable fraction of IB. It can be concluded that BUD needs to 
exit the inhaler persisting on the carrier to ensure proper drug detachment and dis-
persion. IB, however, is already dispersed within the DA and is consequently not de-
pendent on leaving the inhalation device while still being adhered to the carrier. On 
the contrary, the earlier study stated a positive effect for BUD and a negative effect for 
IB. Taking these findings into account, present results hint at different deagglomera-
tion and dispersion behaviour of the two APIs.  
4.4.3 Influence on Device Retention 
For BUD, an extension of grid or an increase in the dimensioning of bottom part re-
duced or increased the fraction of API remaining in device and capsules, respectively. 
Hereby, DRs between 6.5 ± 1.8 % and 32.0 ± 2.5 % were reached (Figure 4-45). A 
quadratic effect of the air inlet/deagglomeration chamber was found as well (Figure 
4-46).  
Results and Discussion 
 
110 
 
 
Figure 4-45 Contour plot of the DR for BUD as a response of the factors grid (repre-
sented by the free grid area) on the x-axis and the bottom part (represented as height 
of the deagglomeration chamber) on the y-axis 
 
Figure 4-46 Illustration of the significant effects of different inhaler parts on the FPF for 
BUD (coefficients scaled and centred). Gained values display the change in DR, if the 
respective factor is changed by one level; MP=Mouthpiece, GR=Grid, 
DA=Deagglomeration chamber 
An increase in DR of the hydrophilic IB was observed when using a large-
dimensioned grid (Figure 4-47), along with a quadratic correlation and an interaction 
between grid and air inlet/deagglomeration chamber (Figure 4-48). IB showed DRs in 
the range of 2.3 ± 0.3 % – 21.5 ± 3.8 %. In contrast to BUD, the bottom part did not 
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have a significant impact on the DR. The choice of the mouthpiece on the remaining 
API fraction was found to be negligible for both APIs.  
 
Figure 4-47 Contour plot of the DR for IB as a response of the factors grid (represented 
by the free grid area) on the x-axis and bottom part (represented as height of the deag-
glomeration chamber) on the y-axis 
 
Figure 4-48 Illustration of the significant effects of different inhaler parts on the FPF for 
IB (coefficients scaled and centred). Gained values display the change in DR, if the 
respective factor is changed by one level; MP=Mouthpiece, GR=Grid, 
DA=Deagglomeration chamber 
Microscopic examination revealed openings with a diameter of ~ 0.6 mm present in 
the small grid. Consequently, GBs potentially clog this grid leading to an insufficient 
emptying of the DA, whereas a larger free grid space allows the interactive mixture to 
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leave the chamber fast and (almost) entirely. This applies to both APIs regardless of 
their chemical properties. The varying effects of the bottom on DR of the two drugs 
were rather complex to interpret. As already pointed out, BUD needs to leave the 
chamber adhered to the GBs for a sufficient detachment during inhalation. A large-
dimensioned bottom part generally provides an extended height of the deagglomera-
tion chamber which leads to an extended distance that the interactive mixture has to 
be lifted to exit the inhaler. An expanded air inlet reduces the air stream velocity. 
Therefore, the more interactive mixture is retained by the inhaler, the more BUD will 
be withheld at the same time. Therefore, the dimensioning of the bottom part signifi-
cantly influences BUD drug retention.  
For IB, the choice of upper and bottom part did not have a significant effect on DR. 
This is because an adequate dispersion and deagglomeration is facilitated even at 
lower air velocities and if the GBs are retained in the deagglomeration chamber. This 
ultimately results in an independence of the amount of drug remaining in the device 
from the dimensioning of the bottom part. 
4.4.4 Influence on Specific Device Resistance 
In addition, the SDR was investigated which is a suitable parameter to compare inha-
lation devices in respect to their resistance. The dimensioning of the upper and bot-
tom part significantly influenced the SDR leading to values between 0.032 and 
0.064 kPa0.5*min/L (Figure 4-49). In addition, an interactive effect of mouthpiece and 
air inlet/deagglomeration chamber was observed (Figure 4-50).  
The impact of upper and bottom part of the inhaler on SDR can be ascribed to a sub-
sequent change in air flow characteristics within the device. If cross sectional area of 
air inlet and mouthpiece are increased this results in an unimpeded air flow through 
the device. In contrast, tightening of respective parts increased the resistance. It can 
also be taken from Figure 4-50 that CSA of the mouthpiece governed the SDR to a 
larger extent. This is due to major differences in the dimensioning of the upper part, 
where one level equalled a gain in area of 14.24 mm² in contrast to the air in-
let (gain of 5.88 mm²). 
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Figure 4-49 Contour plot of the SDR as a response of the factors mouthpiece (repre-
sented by the CSA) on the x-axis and the bottom part (represented as height of the de-
agglomeration chamber) on the y-axis 
 
Figure 4-50 Illustration of the significant effects of different inhaler parts on the SDR 
(coefficients scaled and centred). Gained values display the change in SDR, if the re-
spective factor is changed by one level; MP=Mouthpiece, GR=Grid, 
DA=Deagglomeration chamber 
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4.5 The Importance of API Properties 
Following investigations concerning the importance of inhaler geometry and carrier 
properties, the effect of the second component in an interactive mixture, namely the 
API, on aerodynamic behaviour will be examined in this chapter. To do so, NGI trials 
were conducted employing IB in micronised and BUD in micronised as well as spray-
dried quality. Their respective PSDs can be taken from Figure 4-51. Based on find-
ings from section 4.4, three different Modular Inhaler combinations such as all small 
(Modular_S), all medium (Modular_M) or all large (Modular_L) dimensioned parts 
were selected. The commercially available Cyclohaler was utilised as comparison in 
the present setup. 
Potentially varying dispersion and detachment behaviours have already been pro-
posed for different APIs. To gain a deeper understanding of this process, deposition 
profiles based on impaction data were utilised to display the fraction of API located on 
each stage of the NGI in addition to the resulting FPFs.  
 
Figure 4-51 PSDs (+StD) with logarithmic scaling on the x-axis of BUD in micronised 
and spray-dried quality and IB micro (n=3) 
4.5.1 Micronised versus Spray Dried Budesonide 
Deposition profiles of BUD micro (top) and BUD sd (bottom) when using different in-
halation devices are depicted in Figure 4-52. Here, fractions of API recovered from 
the device, induction port and preseparator as well as from stages of the NGI are dis-
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played. For both API qualities, the DR decreased with increasing dimensioning of the 
Modular Inhaler from 18.3 ± 1.4 % to 9.0 ± 3.2 % (micro) and from 24.2 ± 3.4 % 
to 8.7 ± 1.9 % (sd). An intermediate retention can be ascribed to the Cyclohaler (de-
spite an extended standard deviation). 
 
 
Figure 4-52 NGI deposition profiles (+StD) of BUD micro (top) and BUD sd (bottom) 
from different device settings (n=3) 
Within the preseparator fractions a clear correlation to inhaler dimensioning was ob-
served. API deposition increased from Modular_S up to Modular_L. This trend was 
most prominent for micronised material (35.2 ± 1.0 % to 53.8 ± 3.1 %). In general, 
BUD micro exhibited higher overall fractions in the preseparator compared to BUD sd. 
Overall increased fractions in the induction port were exhibited by BUD micro ranging 
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from 30.1 ± 5.3 % (Cyclohaler) to 34.7 ± 1.2 % (Modular_L). As far as deposition on 
the stages is considered, BUD in spray-dried and micronised quality showed very dif-
ferent results. BUD micro displayed a distribution with a maximum on stages 4 and 5. 
Highest overall fractions of BUD sd were found on stages 2 and 3. 
As expected, maximum DR was observed for Modular_S decreasing over Modular_M 
to L. This is linked to, inter alia, the reduced free grid area which hindered and decel-
erated emptying of the chamber in the Modular_S. Comparable fractions found in 
Modular_M and Cyclohaler can conclusively be related to their similar grid structure 
as single openings were determined as ~ 1.6 mm and ~ 1.7 mm in diameter, respec-
tively. The observation that most GBs were deposited in the preseparator explains 
higher fractions of micronised BUD in this compartment. This is due to a substantial 
proportion of drug still being attached to the carrier after inhalation manoeuvre and 
indicates the presence of extended AFs between micronised drug and carrier. Firstly, 
these might arise from carrier particles applying inertial and frictional forces on drug 
particles during blending [191]. Enhancement of these so-called press-on forces have 
been described to trigger an intimate contact between carrier and API and also to 
force a deformation of particles [192]. Even though blends containing BUD micro were 
blended for a shorter time compared to spray-dried quality (20 min vs. 30 min), the 
intensity was higher in the first case (30 rpm vs. 20 rpm). Since the total energy input 
during blending shows a quadratic relation to mixing speed but increases only linearly 
with the time, major press-on forces are applied to the micronised drug during blend-
ing [193]. Moreover, BUD micro and GBs present a different contact area compared 
to the spray dried counterpart (Figure 4-53).  
 
Figure 4-53 Schematic illustration of plain untreated GB surfaces occupied with spher-
ical spray-dried (left) and irregular shaped micronised drug particles (right) 
Irregular, rather cuboid-shaped particles provide more contact area for interaction with 
the carrier surface. In contrast, spherical particles have fewer contact points leading 
to less potential for interaction [108]. In addition, AFs arising from external press-on 
forces will be limited if contact area is low [193]. Therefore, detachment of micronised 
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particles is impeded compared to the spray-dried drug to ultimately reduce the aero-
dynamic performance.  
Since the SD process resulted in larger particles (x50=2.7 µm) compared to mi-
cronised quality (x50=1.6 µm), extended deposition of BUD sd in the induction port 
cannot be justified by differing size of particles. Instead, higher cohesive forces pre-
sent in the spray-dried material might be accountable. This is supported by observa-
tions made during handling of the spray-dried powder. It appeared rather sticky com-
pared to the micronised drug. In consequence, the tendency of forming agglomerates 
is significantly higher for BUD sd. This is generally in contrast to other research, 
where only minor agglomerate strength was found for spherical particles compared to 
angular- or irregular-shaped ones [194]. It has been acknowledged, however, that 
extended cohesive forces might be present in spray-dried material [195]. This was 
proposed to be due to residual solvent to enhance capillary forces. As those agglom-
erates are mostly deposited in the throat area according to their increased size, depo-
sition in the induction port rises significantly. This is in accordance with a compara-
tively high deposition of BUD sd on NGI stage 1 which has a defined cut-off diameter 
of 8.06 µm at a flow rate of 60 L/min [196]. Although no clear correlation between in-
haler dimensioning and induction port fraction could be established, Modular_S led to 
the lowest deposition in this compartment. On the one hand, this was due to the di-
mensioning of the air-ducting parts as discussed above. On the other hand, the 
smaller grid facilitated drug deagglomeration. 
Different deposition profiles on the stages can be linked to varying particles sizes and 
PSDs. The micronised API was mainly deposited on Stages 4 and 5 with a cut-off 
diameter of 1.66 µm and 0.94 µm, respectively (at 60 L/min). This reflects the PSD 
and the x50 (1.6 µm) of BUD micro very well. It can be assumed that the API fraction 
which was detached from the carrier was also sufficiently deagglomerated. In con-
trast, most BUD sd was recovered from stage 2 with cut-off diameter of 4.46 µm. The 
spray-dried material showed a higher x50 value of 2.7 µm. Nevertheless, it substanti-
ates the suggestion that higher cohesive forces are present for BUD sd. This poten-
tially causes the persistence of drug agglomerates that impact on earlier stages of the 
NGI during inhalation. 
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Figure 4-54 displays FPFs resulting from the corresponding deposition profiles. Re-
gardless of the API quality, Modular_S proved to have the best aerodynamic perfor-
mance (FPF = 31.4 ± 2.1 % for BUD micro and 32.4 ± 1.7 % for BUD sd). Extending 
the dimensioning of inhaler parts reduced the FPF to 14.1 ± 1.3 % (BUD micro) and 
21.1 ± 0.9 % (BUD sd). The Cyclohaler performed comparatively poor which is true 
for both API qualities. 
 
 
Figure 4-54 FPFs (+StD) of blends containing BUD micro (top) or BUD sd (bottom) for 
different inhalers (n=3) 
Respirable fractions gained from the Modular Inhalers can be interpreted with the help 
of findings from section 4.4.2, where a small dimensioning of the respective inhaler 
parts was favourable in any case. This results from an extended airflow within the in-
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haler due to a tight air inlet and mouthpiece. Additionally, the low level of deagglom-
eration chamber and the small grid trigger proper drug dispersion and detachment 
from the carrier. Differences in respirable fractions were more pronounced for the mi-
cronised drug. It is assumed that the different ability of the devices to disperse the 
interactive mixtures has a stronger impact in the presence of comparatively higher 
AFs between GBs and BUD micro. As a consequence, the choice of a suitable inhala-
tion device becomes even more important, when extensive AFs prevail in the powder 
blend. In contrast, BUD sd was found to get properly detached even when using the 
less efficient Modular_L. However an overall better performance was achieved by 
using the Modular Inhaler system compared to the Cyclohaler. 
4.5.2 Budesonide versus Ipratropium Bromide Micronised 
In addition to material quality, the effect of chemical properties of the drug was exam-
ined. To do so, two different APIs, BUD and IB were employed for this study. Interac-
tive mixtures were prepared accordingly with GB_UT.  
 
Figure 4-55 Deposition profiles of IB micro regarding device and different NGI com-
partments 
In general, IB was retained to a lower extent within the device compared to 
BUD (Figure 4-55), but highest (10.4 ± 2.2 %) and lowest (2.2 ± 0.5 %) DRs were also 
gained from Modular_S and Modular_L, respectively. Fewer overall amount of drug 
was found in the induction port ranging from 12.3 ± 1.3 % to 18.0 ± 3.6 %. Fractions 
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recovered from the preseparator were found to be between 38.1 ± 1.4 % and 
67.2 ± 1.9 %. Looking at NGI stages, most API was recovered from stages 4 (3.6 ± 
0.5 % – 10.7 ± 0.3 %) and 5 (1.5 ± 0.2 % – 8.7 ± 0.2 %). On stages 3 to 7, most API 
was found for Modular_S, whereas Cyclohaler triggered highest deposition on stages 
1 and 2. 
The overall lower DR compared to BUD can be accounted to the chemical character-
istics of GBs and IB. Due to their hydrophilic nature, extended attractive forces are 
present between the two. It is assumed that this leads to a reduced drug detachment 
during processing of the interactive mixture (capsule filling). Consequently, a smaller 
amount of API is recovered from the device and inserted capsules. Higher overall 
fractions of IB in the preseparator can conclusively be explained that way as well. Ex-
tended attractive forces increase the potential for a persisting adhesion of the API 
during inhalation. Therefore, the airstream detached less IB from the carrier. Different 
deposition profiles on the NGI stages for IB and BUD are due to differing PSDs of the 
two drugs (Figure 4-51). Lowest deposition on stages 1 and 2 as well as highest dep-
osition on stages 3 – 7 observed for Modular_S also display an enhanced dispersion. 
In contrast, the stage deposition exhibited by the Cyclohaler display the opposing 
trend compared to Modular_S. This indicates a rather poor aerodynamic performance 
of the Cyclohaler.  
 
Figure 4-56 FPFs of blends containing IB micro for different inhalers  
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Figure 4-56 shows fine particle fractions as the result of using various inhalation de-
vices under investigation. A clear trend was observed concerning the Modular Inhaler 
system, where a downsizing of the inhaler dimensioning enhanced the FPF 
from 14.7 ± 0.3 % (Modular_L) to 34.7 ± 1.7 % (Modular_S). The Cyclohaler present-
ed a low value of 12.0 ± 1.2 %. 
Taking findings obtained from hydrophobic BUD into account demonstrates that both 
APIs show a similar aerodynamic performance for the respective modular inhaler 
combination. It can be concluded that the overall effect of device dimensioning is 
widely the same for different drugs, regardless of their chemical properties. Moreover, 
when using GBs as carrier, the device should generally have a small dimensioning to 
increase the resistance and consequently the air stream velocity within the device to 
ensure proper drug detachment.  
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5 Overall Conclusion and Future Perspectives 
The present work highlights the importance of carrier surface properties on interparti-
cle interactions in DPI formulations. It is shown that these interactions play a key role 
for a successful pulmonary drug delivery and also determine the effective drug load 
and thus, have to be taken into consideration. Moreover, the choice of inhaler, or 
more precisely, its conception is critical as air flow velocity within the device and also 
dispersion principle govern the aerodynamic performance.  
The first part of this thesis clearly revealed that spray drying was a suitable technique 
to produce drug powders with the desired material properties (PSD, shape). Here, 
process parameters have to be chosen thoughtfully to control particle size and also 
maintain an efficient process. This was material dependent, thus this evaluation 
needs to be done for each API. Nonetheless, the study shows that it is possible to set 
particle properties for a wide range of materials. 
To systematically investigate the impact of carrier surface characteristics on interpar-
ticle interactions, GBs were utilised as a model carrier system. The chemical proper-
ties of the carrier significantly influenced the FPF of the hydrophobic model 
drug (BUD), while this effect became less prominent for the more hydrophilic model 
APIs (FF, TB). It also became evident that the FPD needs to be considered as well 
when evaluating the aerodynamic performance. This was because carrier surface 
modification did not only affect the FPF but also impacted the effective drug load-
ing (TSC). As already suggested, the control of adhesive forces, e.g. by lowering of 
van-der-Waals forces, is of great importance in that context. Even though major ad-
hesion potentially increases blend homogeneity and drug load, it reduces the proba-
bility for drug detachment and ultimately drug delivery efficiency. It can be derived 
from the present investigation that surface chemistry of the carrier is especially im-
portant for formulations with more hydrophobic drugs like corticosteroids. Here, it de-
termines not only the effective drug load, but also the overall aerodynamic perfor-
mance. 
The alteration of surface topography proved to determine the aerodynamic perfor-
mance as well. Although the introduction of nano-scale roughness showed to nega-
tively influence the TSC, it increased the overall aerodynamic performance of 
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the API (FPF and FPD). This was regardless of chemical nature of the drug. De-
creased AFs between carrier and API were measured by AFM and could be identified 
as the major cause for this. Indentations on micro scale, however, should be avoided 
for an optimal drug delivery since they can shelter API particles from drag and lift 
forces during inhalation. This is particularly important when using inhalation devices 
which rely on those forces for drug detachment and deagglomeration, e.g. the Cyclo-
haler. Indentations can shelter API particles from those forces during inhalation. Iner-
tial impaction, however, affects all particles the same way, regardless of their position 
leading to a negligible effect of larger carrier discontinuities for devices such as the 
Novolizer. These findings especially apply to round-shaped drug particles. When us-
ing drugs of angular or needle-like shape its orientation on the carrier becomes of im-
portance as well. This might induce other interactions, e.g. mechanical interlocking. 
The third part demonstrated the importance of the device conception on drug delivery. 
A systematic investigation on the influence of the dimensioning of essential inhaler 
parts in comparison with an earlier study clearly demonstrated the interplay between 
formulation and device. While an overall small dimensioning was widely favourable for 
GBs, large-dimensioned inhaler parts showed improved aerodynamic performance for 
blends containing lactose. Predicting the performance of a specifically designed de-
vice is very difficult since this will be also highly dependent on material properties of 
the carrier and also the dispersion behaviour of the API. Therefore, a general formula 
for the “perfect” device cannot be provided but rather has to be always seen in com-
bination with the respective formulation. Nevertheless, the present study drew im-
portant conclusions from the comparison of two carriers with extensively different 
properties and might therefore contribute to the design of future inhalation devices. 
Future research should focus on implementing introduced surface modifications to a 
conventional carrier and compare obtained results to the present findings. Initially, this 
would comprise the establishment of suitable modification techniques.  
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6 Summary 
The design of formulations intended for inhalation is a major challenge since many 
different factors need consideration in order to guarantee major drug delivery. This 
becomes especially important in dry powder inhalation. Balanced interparticle interac-
tions between carrier and API are key factors for an optimal aerodynamic perfor-
mance. In addition, the inhalation device is also of great importance. Its conception 
and dimensioning determine flow of the airstream within the device and dispersion 
principle. 
Therefore, the focus in the present thesis is put on the investigation of factors, which 
influence interparticle interactions. This should enable a deeper understanding of 
them and their impact on the behaviour of the powder blend. Ultimately, findings shall 
facilitate the development of new dry powder inhaler formulations and the choice of 
the suitable device for an optimal drug delivery. For this, glass beads (GBs) were 
chosen as a model carrier system to selectively alter their surface. 
Initially, drug powders were manufactured via spray drying. To cover a wide range of 
active pharmaceutical ingredients (APIs), hydrophobic budesonide (BUD), formoterol 
fumarate (FF) and hydrophilic tiotropium bromide (TB) were selected. The influence of 
process parameters on material properties was examined within experimental de-
signs. By that, it was possible to produce particles in the desired size range 
of 1 to 5 µm and also optimise the spray drying process in terms of resulting prod-
uct yield. 
In order to investigate the impact of chemical surface properties of the carrier, these 
were altered by a targeted silanisation of the GB surface with different agents. This 
led to an enhanced hydrophobicity displayed by an increase in contact angle 
from 24.0 ° to 86.1 °. This modification also influenced the dispersive part of the sur-
face energy (28.0 – 61.4 mJ/m²) as shown by inverse gas chromatography measure-
ments. A positive correlation between hydrophobicity and effective drug loading was 
shown for the hydrophobic BUD. Impaction analysis using the Next Generation Phar-
maceutical Impactor, however, showed that the fine particle fraction (FPF) was re-
duced from 19.5 % to 11.2 %. This was due to increased AFs between carrier and 
API. This highlights the necessity to control these adhesive forces by, inter alia, alter-
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ation of carrier surface chemistry. Moreover, a dependency on the dispersive surface 
energy was found. Further experiments demonstrated that the correlation of drug 
loading and FPF to carrier surface chemistry was less pronounced or even insignifi-
cant with increased hydrophilicity of the API. 
Furthermore, the influence of carrier surface roughness was investigated for BUD and 
FF. The incubation with hydrofluoric acid and/or ball milling with tungsten carbide 
successfully altered topographical parameters, i.e. introduced roughness on micro- 
and/or nano-scale to the GB surface. This was examined via scanning electron and 
atomic force microscopy. The modifications proved to influence the effective drug 
loading. Moreover, they had a major impact on the aerodynamic performance as mi-
cron-sized indentations drastically reduced the FPF. This could be linked to their abil-
ity to shelter drug particles from the airstream during inhalation. Nano-scale rough-
ness on the other hand led to a significant increase of the FPF up to 28.2 % (FF). 
These trends were also existent when using BUD. This clearly demonstrated the gen-
eral validity of these findings regardless of chemical properties of the API. 
The importance of a capsule-based inhalation device was examined as well. Here, an 
experimental design was applied to identify important inhaler parts and the impact of 
their dimensioning. The air-ducting parts as well as the grid (separating capsule 
chamber and mouthpiece) significantly altered the FPF of the investigated drugs BUD 
and ipratropium bromide between 14.3 % to 31.4 % and 14.7 % to 35.2 %, respec-
tively. It was concluded that in case of GBs, an overall small dimensioning of the de-
vice leading to a high velocity of air is favourable for an optimal drug delivery. In addi-
tion, API properties such as crystallinity, shape and size also had a significant effect 
on aerodynamic performance since they triggered varying cohesive and adhesive 
forces as well as a different contact area. 
This thesis presents the systematic investigation on the effect of carrier surface prop-
erties on the aerodynamic performance and therefore contributes substantially to a 
deeper comprehension of interparticle interactions between carrier and API. Addition-
ally, the importance of the inhalation device, or more precisely its dimensioning, could 
be demonstrated. Present findings also showed that the efficient drug delivery is high-
ly dependent on the interplay between device and formulation.  
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7 Summary (German) 
Das Formulierungsdesign für inhalative Zubereitungen stellt eine große Herausforde-
rung dar, da eine Reihe von Faktoren beachtet werden muss, um einen optimalen 
Transport des Wirkstoffes in die Lunge sicherzustellen. Allerdings kommt einer opti-
mierten Formulierung grade bei der Trockenpulverinhalation eine besondere Bedeu-
tung zu. Die Balance der interpartikulären Wechselwirkungen zwischen Arzneistoff 
und Träger ist hier entscheidend für eine effektive Wirkstoffdeposition. Ferner spielt 
auch der Inhalator selbst eine besondere Rolle. Dessen Aufbau und Dimensionierung 
bestimmen den Luftfluss im Inneren sowie das Dispergierprinzip.  
Aus diesem Grund liegt der Fokus der vorliegenden Arbeit auf der Untersuchung von 
Faktoren, die die interpartikulären Wechselwirkungen beeinflussen. Hierbei soll ein 
tieferes Verständnis dieser Faktoren und deren Einfluss auf das Verhalten der Pul-
vermischungen erhalten werden, um letztendlich die Entwicklung neuer Formulierun-
gen für die Trockenpulverinhalation und die Wahl des passenden Inhalators vereinfa-
chen. Hierfür wurden Glaskugeln (GBs) als Modellträgersystem ausgewählt und de-
ren Oberfläche gezielt modifiziert.  
Zunächst wurden geeignete Wirkstoffpulver über Sprühtrocknung hergestellt. Um ein 
breites Wirkstoffspektrum mit unterschiedlichen chemischen Eigenschaften zu unter-
suchen, wurden Budesonid, Formoterolfumarat und Tiotropiumbromid ausgewählt. Im 
Rahmen eines experimentellen Versuchsplans wurde der Einfluss der Prozesspara-
meter der Sprühtrocknung auf Materialeigenschaften des Produkts untersucht. So 
konnten hierbei Partikel mit der erwünschten Größe von 1 bis 5 µm hergestellt wer-
den. Außerdem konnte die Prozessausbeute optimiert werden. 
Um den Effekt der chemischen Oberflächeneigenschaften des Trägers zu untersu-
chen, wurde eine unterschiedliche Beschaffenheit der Oberfläche durch eine gezielte 
Silanisierung mit unterschiedlichen Agenzien herbeigeführt. Dies verringerte die Hyd-
rophilie, was durch einen Anstieg des gemessenen Kontaktwinkels von 24.0 ° auf bis 
zu 86.1 ° bestätigt wurde. Untersuchungen mittels inverser Gaschromatographie zeig-
ten, dass gleichzeitig auch die dispersive Oberflächenenergie verändert wur-
de (28,0 – 61,4 mJ/m²). Für das hydrophobe Budesonid konnte eine positive Korrela-
tion der Hydrophobizität zur effektiven Oberflächenbeladung des Trägers gezeigt 
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werden. Impaktionsversuche mit dem Next Generation Pharmaceutical Impactor zeig-
ten allerdings, dass die inhalierbare Fraktion (FPF) durch diesen Prozess von 19,5 % 
auf 11,2 % gesenkt wurde. Es konnte mithilfe der Rasterkraftmikroskopie gezeigt 
werden, dass dies das Resultat steigender Adhäsionskräfte zwischen Träger und 
Wirkstoff war. Dies verdeutlicht, welch große Bedeutung diesen adhäsiven Kräften 
zukommt, und dass sie, zum Beispiel über eine Modifizierung der Oberflächenchemie 
des Trägers, verändert werden sollten um eine optimale Wirkstoffdeposition zu erhal-
ten. Im weiteren Verlauf zeigte sich aber eine abnehmende Signifikanz dieser Korre-
lationen mit steigender Hydrophilie des Wirkstoffes. 
Des Weiteren wurde der Effekt einer veränderten Oberflächenrauheit für zwei unter-
schiedliche Wirkstoffe (Budesonid, Formoterol) genau untersucht. Die hierfür einge-
setzten Techniken (Inkubation mit Flusssäure, Mahlung mit Wolframcarbid) führten zu 
einer erfolgreichen Einführung von Mirko- und/oder Nanorauheit auf der Oberfläche. 
Dies wurde mithilfe der Rasterelektronen- und Rasterkraftmikroskopie verdeutlicht. 
Diese Modifikationen hatten einen signifikanten Einfluss auf die Wirkstoffbeladung 
des Trägers. Darüber hinaus reduzierten die Mikrorauheiten die inhalierbare Fraktion 
deutlich, was deren Fähigkeit, die Wirkstoffpartikel vor dem Luftstrom zu schützen, 
zugeschrieben werden konnte. Nanorauheit führte hingegen zu einer deutlichen Stei-
gerung der FPF bis zu 28.2 % (für Formoterol). Diese Trends konnten auch für Bude-
sonid gezeigt werden, was deren Allgemeingültigkeit unabhängig von den chemi-
schen Eigenschaften des Wirkstoffes deutlich macht. 
Im weiteren Verlauf dieser Arbeit wurde auch die Bedeutung des Inhalators (kapsel-
basiert) untersucht. Im Rahmen eines experimentellen Versuchsplans wurde hier der 
Einfluss der Dimensionierung verschiedener Bauteile geprüft und direkt mit früheren 
Untersuchungen verglichen, in denen Laktose als Träger verwendet wurde. Die luft-
führenden Bauteile sowie der Gittereinsatz, der die Deagglomerationskammer vom 
Mundstück trennt, zeigten deutliche Effekte auf die FPF der untersuchten Wirkstoffe 
Budesonid und Ipratropiumbromid, die von 14,3 % bis 31,4 % bzw. 14,7 % bis 35,2 % 
reichte. Dabei wurde deutlich, dass im Falle der GBs eine kleine Dimensionierung 
aller untersuchten Bauteile vorteilhaft für eine optimale Deposition des Wirkstoffs in 
der Lunge ist. Dies wurde einer erhöhten Geschwindigkeit des Luftstroms im Inhalator 
zugeschrieben. Des Weiteren zeigten Untersuchungen bezüglich der Materialeigen-
schaften (Kristallinität, Partikelform und -größe), dass auch diese einen deutlichen 
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Einfluss auf das aerodynamische Verhalten der Mischung zeigten. Dies wurde durch 
ein unterschiedliches Maß an Kohäsions- und Adhäsionskräften und durch unter-
schiedlich große Kontaktflächen bedingt. 
Die vorliegende Arbeit trägt mit der systematischen Untersuchung der Effekts unter-
schiedlicher Eigenschaften der Trägeroberfläche auf das aerodynamische Verhalten 
der Mischung wesentlich zu einem tiefgreifenden Verständnis der interpartikulären 
Wechselwirkungen zwischen Arzneistoff und Träger bei. Des Weiteren konnte die 
Bedeutung des Inhalators bzw. dessen Dimensionierung für eine optimale Wirkstoff-
deposition in der Lunge verdeutlicht werden. Hierbei zeigte sicher aber auch, dass die 
Effektivität, mit der der Wirkstoff in die Lunge gebracht wird, deutlich von einem Zu-
sammenspiel von Inhalator und Formulierung abhängt. 
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8 Appendix 
8.1 HPLC Methods 
8.1.1 Budesonide 
Mobile phase:  25 % ddH2O 
75 % Methanol 
 
Column: LiChroCART® 125-4, LiChrospher® 100 RP-18 (5 µm) with 
precolumn 
 
Flow rate:   1.0 mL/min 
 
Wavelength:   248 nm 
 
Injection volume:  100 µL 
 
Oven temperature  25°C 
 
Samples were dissolved in ddH2O:methanol 25 %:75 % (V/V) 
8.1.2 Formoterol Fumarate 
Mobile phase: 45 % buffering system (2.34 g/L sodium octansulfonate 
and 1.38 g/L NaH2PO4•H2O, pH adjusted to 3.2 with ortho-
phosphoric acid 85 %)     
 40 % methanol 
 15 % acetonitrile    
 
Column:                        LiChroCART 125-4, LiChrospher RP select B (5 µm)         
with precolumn 
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Flow rate:   1.2 mL/min 
 
Wavelength:   214 nm 
 
Injection volume:  100 µL 
 
Oven temperature  25°C 
 
Samples were dissolved in ddH2O:methanol:acetonitrile 45 %:40 %:15 % (V/V) 
8.1.3 Ipratropium Bromide 
Mobile phase: 71 % buffering system (1.42 g/L sodium heptanesulfonate, 
pH adjusted to 3.3 with ortho-phosphoric acid 85 %)     
 29 % acetonitrile    
 
Column:                        LiChroCART® 125-4, LiChrospher® 100 CN (5 µm) with 
precolumn 
 
Flow rate:   1.2 mL/min 
 
Wavelength:   220 nm 
 
Injection volume:  100 µL 
 
Oven temperature  25°C 
 
Samples were dissolved in ddH2O 
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8.1.4 Tiotropium Bromide 
Mobile phase: 71 % buffering system (1.42 g/L sodium heptane-sulfonate, 
pH adjusted to 3.2 with ortho-phosphoric acid 85 %)     
 29 % acetonitrile    
 
Column:                        LiChroCART® 125-4, LiChrospher® 100 CN (5 µm) with 
precolumn 
 
Flow rate:   1.2 mL/min 
 
Wavelength:   239 nm 
 
Injection volume:  100 µL 
 
Oven temperature  25°C 
 
Samples were dissolved in ddH2O 
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8.2 Materials 
Acetone     Sigma-Aldrich, Inc., St. Louis, USA 
Acetonitrile     Sigma-Aldrich, Inc., St. Louis, USA 
Brij® 35  Carl Roth GmbH & Co. KG, Karlsruhe, Ger-
many 
Budesonide  Minakem SAS, Dunkerque, France 
Decane Sigma Aldrich  
ddH2O  freshly produced with Finn Aqua 75, San-
Asalo-Sohlberg Corp., Helsinki, Finnland 
Ethanol Merck KGaA, Darmstadt, Germany 
Formoterol fumarate Vamsi Labs Ltd., Maharashtra, India 
Glass beads (SiLibeads®) Sigmund Lindner GmbH, Warmensteinbach, 
Germany 
Glycerol Merck KGaA, Darmstadt, Germany 
Helium 5.0 Linde AG, Munich, Germany 
Heptan Merck KGaA, Darmstadt, Germany 
Hexane Sigma-Aldrich, Inc., St. Louis, USA 
Hydrofluoric acid 38 % Merck KGaA, Darmstadt, Germany 
Hydrogen 5.0 Linde AG, Munich, Germany 
Ipratropium bromide Boehringer Ingelheim Pharma AG & Co. KG 
Methanol Merck KGaA, Darmstadt, Germany 
Methylene chloride AppliChem GmbH, Gatersleben, Germany 
Nitrogen 5.0 Linde AG, Munich, Germany 
Nonane Sigma-Aldrich, Inc., St. Louis, USA 
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Octane Sigma-Aldrich, Inc., St. Louis, USA 
o-Phosphoric acid Merck KGaA, Darmstadt, Germany 
Sodium heptansulphonate Carl Roth GmbH & Co. KG, Karlsruhe, Ger-
many 
Sodium octansulphonate Arcos Organics, Geel, Belgium 
Tiotropium bromide Hangzhou Hyper Chemicals Ltd., Zhejiang, 
China 
Tungsten carbide Wolfram Bergbau und Huetten AG, St. Martin 
i.S., Austria 
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8.3 Abbreviations 
AFM      Atomic force microscopy 
API      Active pharmaceutical ingredient 
APSD      Aerodynamic particle size distribution 
BFE      Basic flowability energy 
BUD      Budesonide 
CAB      Cohesive-adhesive balance 
CDPMS     Chloro(methyl)diphenylsilane 
COPD     Chronic obstructive pulmonary disease 
CSR      Cross sectional area 
DD      Delivered dose 
DR      Device retention 
ddH2O      Double distilled H2O 
DGF      Drying gas flow 
DoE      Design of experiments 
DPI      Dry powder inhaler 
DR      Device retention 
DVS      Dynamic vapour sorption 
ED      Emitted dose 
FC      Feed concentration 
FF      Formoterol fumarate 
FPD      Fine particle dose 
FPF      Fine particle fraction 
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FPTS      Trimethoxy(3,3,3-trifluoropropyl)silane 
FR      Feed rate, % 
GB      Glass bead 
HF      Hydrofluoric acid 
HPLC      High performance liquid chromatography 
IB      Ipratropium bromide 
ICS      Inhaled corticosteroids 
iGC      Inverse gas chromatography 
LAMA      Long-acting muscarinic antagonist 
micro      Micronised 
MMAD     Mass median aerodynamic diameter 
NGI      Next Generation Pharmaceutical Impactor 
pMDI      Pressurised metered-dose inhaler 
PSD       Particle size distribution 
RD      Recovered dose 
rH      Relative humidity 
rpm      Rounds per minute 
Rrms      Root mean square of surface roughness 
rStD      Relative standard deviation 
SD      Spray drying 
sd      spray-dried 
SDR      Specific device resistance 
SEM      Scanning electron microscopy 
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SGF      Spray gas flow, L/h 
StD      Standard deviation 
TB      Tiotropium bromide 
TC      Tungsten carbide 
Tinlet      Inlet temperature °C 
TPCS      Chlorotiphenylsilane 
WFA      Wall friction angle 
XRPD      X-ray powder diffraction 
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8.4 Formula Symbols 
𝑐𝑥      Coefficient 
γs
d      Dispersive surface energy, mJ/m² 
𝑑      Diameter 
𝐷      Diffusion coefficient 
𝑓𝑛      Factor level 
𝑔      Gravitational acceleration, m/s² 
Ƞ      Viscosity, Pa*s 
𝑘      Boltzmann´s constant, J/K 
𝑚      Mass, kg 
𝑛/𝑛𝑚      Surface occupancy 
𝑝𝑎      Air density, kg/m³ 
𝑃𝐸𝑄𝑃𝐶      Perimeter of the equivalent circle, m 
𝑃𝑟𝑒𝑎𝑙      Real perimeter, m 
𝑝𝑝      Particle density, kg/m³ 
𝑝0      H2O density, kg/m³ 
𝑄      Air flow, m/s 
𝑄2      Indicator for future prediction precision 
𝑄3      Cummulative volume-based distribution, % 
𝑞3 ∗      Probability density function 
𝑅2      Indicator for model significance 
𝑆𝐴      Surface area, m² 
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𝑆𝑝ℎ      Sphericity 
𝑆𝑡𝑘      Stokes´ number 
𝑉      Velocity, m/s 
𝑉𝑡𝑠      Terminal settling velocity, m/s 
𝛸      Shape factor 
𝑥10      10 % quantile of the PSD 
𝑥50      Median of the PSD 
𝑥90      90 % quantile of the PSD 
𝑦      Response to the respective factors 
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8.5 Overview of Experimental Designs 
8.5.1 Spray Drying of Budesonide (section 4.1.1) 
Exp. No. Run Order 
Inlet  
Temperature, °C 
Feed rate, % 
Feed  
concentration, % 
1 15 80 6 4 
2 5 120 6 4 
3 13 80 10 4 
4 9 120 10 4 
5 10 80 6 10 
6 14 120 6 10 
7 3 80 10 10 
8 6 120 10 10 
9 16 80 8 7 
10 18 120 8 7 
11 4 100 6 7 
12 19 100 10 7 
13 1 100 8 4 
14 17 100 8 10 
15 12 100 8 7 
16 11 100 8 7 
17 7 100 8 7 
18 2 100 8 7 
19 8 100 8 7 
 
  
Appendix 
 
140 
 
8.5.2 Spray Drying of Formoterol Fumarate (section 4.1.2) 
Exp. No. Run Order Feed rate, % 
Spray gas 
flow, L/h 
Feed  
concentration, % 
1 18 4 334 2.5 
2 11 8 334 2.5 
3 17 4 334 7.5 
4 2 8 334 7.5 
5 6 4 426 2.5 
6 9 8 426 2.5 
7 7 4 426 7.5 
8 13 8 426 7.5 
9 15 4 380 5 
10 19 8 380 5 
11 3 6 380 2.5 
12 8 6 380 7.5 
13 16 6 334 5 
14 10 6 426 5 
15 4 6 380 5 
16 1 6 380 5 
17 12 6 380 5 
18 5 6 380 5 
19 14 6 380 5 
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8.5.3 Spray Drying of Tiotropium Bromide (section 4.1.3) 
Exp. No. Run Order 
Inlet 
temperature, °C 
Spray gas 
flow, L/h 
Feed  
concentration, % 
1 9 120 380 2 
2 14 120 380 4 
3 11 120 496 2 
4 7 120 496 4 
5 15 150 380 2 
6 16 150 380 4 
7 19 150 496 2 
8 8 150 496 4 
9 12 135 438 2 
10 10 135 438 4 
11 2 135 380 3 
12 6 135 496 3 
13 4 120 438 3 
14 3 150 438 3 
15 1 135 438 3 
16 17 135 438 3 
17 18 135 438 3 
18 5 135 438 3 
19 13 135 438 3 
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8.5.4 The Importance of Inhaler Geometry (section 4.4.1) 
Exp. No. Run Order 
Mouthpiece, Cross 
sectional area, mm² 
Grid, Free grid 
area, mm 
Deagglomeration 
chamber, Height, mm 
1 19 7.06 20.71 7 
2 2 35.54 20.71 7 
3 16 7.06 50.80 7 
4 3 35.54 50.80 7 
5 5 7.06 20.71 9 
6 6 35.54 20.71 9 
7 7 7.06 50.80 9 
8 11 35.54 50.80 9 
9 9 7.06 35.76 8 
10 10 35.54 35.76 8 
11 4 21.30 20.71 8 
12 15 21.30 50.80 8 
13 8 21.30 35.76 7 
14 13 21.30 35.76 9 
15 14 21.30 35.76 8 
16 12 21.30 35.76 8 
17 1 21.30 35.76 8 
18 18 21.30 35.76 8 
19 17 21.30 35.76 8 
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